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Abstract
Connexin 26 (Cx26) and Cx30 mediate the intercellular exchange of metabolites and ions
within the cochlea in a process known as gap junctional intercellular communication (GJIC).
Cochlear cell death and subsequent hearing loss can arise after treatment with ototoxic
therapeutics and Cx26 mutant expression. We investigated the role of connexins and GJIC in
the development of ototoxicity in HEI-OC1 cochlear-derived cells. The susceptibility of HEIOC1 cells to aminoglycoside antibiotics and cisplatin-induced cell death was not influenced
by the ablation of connexins and GJIC. However, the expression of mitochondrial apoptosis
or ER stress markers was altered by the degree of GJIC. Hearing loss linked Cx26 syndromic
mutants (N54K and S183F) displayed diverse gain-of-function properties in HEI-OC1 cells.
However, non-syndromic mutants (R32H and R184P) displayed similar loss-of-function
properties. Collectively, these disease-linked Cx26 mutants exhibited three distinct cellular
phenotypes, which may contribute to unique mechanisms for hearing loss in vivo.
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Lay Summary
Cells can communicate by expressing connexin proteins that form gap junction channels
between adjacent cells in the majority of tissues throughout the body. These channels allow
the transfer of ions and signalling molecules between cells in a process known as gap
junctional intercellular communication (GJIC). GJIC is important for cellular health and
facilitating in countless physiological processes. Twenty-one different connexin family
members exist, including connexin 26 (Cx26), which is highly expressed in the cochlea. The
cochlea is located in the inner ear and contains hair cells that allow for sound detection. Cx26
channels and GJIC help maintain hair cell survival in the cochlea. Hair cell death and
resulting hearing loss is a result of treatment with particular medications called ototoxic
drugs. GJIC can potentially propagate death signals to healthy cells and increase cell death as
seen in cancer cells. We found that connexin expression and GJIC did not enhance apoptosis
after treatment with ototoxic therapeutics in cochlear-derived cells. However, the degree of
GJIC altered the pathways leading to cell death, potentially by altering which molecules
could travel between cells. Hearing loss can also arise from mutations in the gene encoding
for Cx26. Cx26 mutations result in ~50% of all inherited hearing loss worldwide. Around
135 different Cx26 mutations that induce hearing loss have been identified. Proper connexin
trafficking to the cell surface and channel formation is important for connexin function. Cx26
mutants can exhibit loss-of-function properties including improper connexin channel
trafficking to the cell surface and defective channel function. Gain-of-function properties
include the ability of the Cx26 mutant to interact with other connexin family members
impairing or enhancing their function. We analyzed the cellular localization of four hearing
loss linked Cx26 mutants in cochlear-derived cells to improve our understanding of the
various hearing loss mechanisms. Cx26 mutations that result in hearing loss and a skin
disease primarily displayed gain-of-function properties, whereas mutations that only cause
hearing loss had loss-of-function properties. Overall, we identified three distinct mechanisms
for hearing loss between the mutants studied, suggesting that future therapeutic strategies
will need to account for the specific nature of connexin defect.
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Chapter 1
1

Literature Review

1.1 Connexins, Gap Junctions, and Gap Junctional Intercellular
Communication
Connexins are gap junction proteins that oligomerize into hexameric channels called
connexons. Connexons can form channels at the plasma membrane known as
hemichannels; moreover, they can also dock between adjacent cells to facilitate direct
intercellular exchange of metabolites, ions, and small molecules <1 kDa in a process
known as gap junctional intercellular communication (GJIC) (Goodenough and Paul,
2009). Connexins and GJIC are vital for cellular growth, proliferation, differentiation,
and apoptosis (Bruzzone et al., 1996; Goodenough et al., 1996). Within the human body,
the connexin gene family is composed of 21 different connexin isoforms, with at least
one connexin isoform expressed in almost all mature and developing cells (Aasen et al.,
2018; Willecke et al., 2002). Within a particular cell multiple connexin isoforms can be
co-expressed; therefore, connexons can be composed of one connexin isoform
(homomeric) or made up of various connexin isoforms (heteromeric) (Goodenough and
Paul, 2009). Additional complexity is added when two connexons dock between adjacent
cells to generate homotypic or heterotypic connexin channels. Homotypic channels are
composed of the same connexons docking between adjacent cells; in contrast, heterotypic
channels are formed by different connexons (Mese et al., 2007; White and Bruzzone,
1996). Heterotypic connexin channels confer the advantage of increasing or altering the
selective permeability of gap junction channels in comparison to homotypic counterparts
(Goldberg et al., 2004). Connexin isoforms can be segregated into five separate
subfamilies based on their sequence homology: alpha, beta, gamma, delta, and epsilon.
The connexin sequences within these subfamilies influences their oligomerization
capacity (Koval et al., 2014; Vinken, 2015; White and Bruzzone, 1996). For example,
connexin 26 (Cx26) is a part of the beta family and is typically incapable of
oligomerizing and forming heteromeric connexons with the alpha connexin, Cx43 (Falk,
2000; Gemel et al., 2004). Additionally, connexins are identified based on their molecular
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weight - for example Cx26 is 26kDa (Beyer et al., 1990). Each connexin isoform is
composed of four transmembrane domains, two extracellular loops involved in the
docking of connexons, one intracellular loop, and cytoplasmic carboxy and amino termini
(Sohl and Willecke, 2004). The carboxy terminus is the most variable domain between
connexin isoforms and is important for binding of cytoplasmic signaling proteins that
influence gap junction-independent functions (Dbouk et al., 2009; Leithe et al., 2018).
Additionally, the carboxy terminus of connexins can be phosphorylated, which has been
extensively studied in regard to the trafficking and stability of Cx43 at the plasma
membrane (Lampe and Lau, 2000).

1.2 Connexin Life Cycle
The biosynthesis of connexin proteins begins with the co-translation integration of
connexin proteins into the endoplasmic reticulum (ER) membrane by ER associated
ribosomes (Falk et al., 1994). Additionally, connexins begin to oligomerize into
connexons within the ER, with the exception of Cx43 and Cx46 where oligomerization
occurs in the Golgi apparatus (Ahmad et al., 1999; Musil and Goodenough, 1993).
Connexin export to the plasma membrane then follows the traditional ER-Golgi secretory
pathway, including microtubule facilitated trafficking to the plasma membrane (Segretain
and Falk, 2004; Shaw et al., 2007; Thomas et al., 2005). Oddly, Cx26 has been reported
to be post translationally inserted into the ER membrane and may be directly inserted into
the plasma membrane (Ahmad and Evans, 2002); however, it is unclear if this occurs in
vivo (Laird, 2006). Once connexons reach the plasma membrane they dock with
connexons from an adjacent cell and form large gap junction plaques that are in a
dynamic state within the lipid bilayer (Lauf et al., 2002). The majority of connexin
isoforms have a one to five-hour half-life (Berthoud et al., 2004; Falk et al., 2014; Fallon
and Goodenough, 1981). Older connexons are recycled from the center of gap junction
plaques and are internalized via double membrane vesicles termed connexosomes or
annular junctions (Laird, 2006; Lauf et al., 2002). These connexosomes then undergo
degradation through autophagy, proteasomal degradation, or fuse with early endosomes
to be degraded in lysosomes (Aasen et al., 2019; Falk et al., 2009; Laing et al., 1997;
Musil et al., 2000; Qin et al., 2003). The level of GJIC can therefore be dynamically
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regulated in response to changing physiological conditions due to the short half-life of
connexins (Berthoud et al., 2004).

1.3 Gap Junctions Within the Cochlea
GJIC plays a critical role in the development and homeostasis of the organ of Corti
within the cochlea (Zhao et al., 2006; Zhu et al., 2015). The two main connexin isoforms
expressed in the organ of Corti are Cx26 and Cx30 (Forge et al., 2003; Liu et al., 2009).
The organ of Corti contains two types of hair cells: one row of inner hair cells (IHC) and
three rows of outer hair cells (OHC) (Chen et al., 2009). IHCs are the mechanosensory
cells that transform mechanical energy into electrical signals for the brain to perceive
sound (Chen et al., 2009). OHCs are responsible for increasing the sensitivity of the
cochlea to sound by altering their length via the motor protein prestin (Chen et al., 2009;
Zheng et al., 2000). Cx26 and Cx30 have been found to oligomerize into heteromeric and
heterotypic gap junctions to form two distinct gap junction networks in the cochlea: the
epithelial and connective tissue networks (Ahmad et al., 2003; Forge et al., 2003; Kikuchi
et al., 1995; Liu et al., 2009). These networks contain some of the largest gap junction
plaques in the body (Forge et al., 2003). The epithelial gap junction network is present
between the non-sensory supporting cells that surround the hair cells, however there is no
GJIC between hair cells and supporting cells (Forge et al., 2003). The connective tissue
gap junction network exists between resident cells of the connective tissue found in the
cochlear lateral wall, including fibrocytes, intermediate, and basal cells (Forge et al.,
2003). These gap junction networks have been proposed to be important in buffering and
recycling potassium ions (K+) back into the endolymph fluid that bathes the hair cells
after hair cell stimulation (Jagger and Forge, 2015; Jagger et al., 2010). High
endolymphatic K+ concentrations are necessary to produce a gradient for K+ to depolarize
hair cells and produce signals for the brain to detect sound (Jagger et al., 2010).
Additionally, these networks are implicated in the proper cochlear development and
maturation by facilitating the movement of secondary messengers and essential miRNAs
(Johnson et al., 2017; Liang et al., 2012; Zhu et al., 2015). Moreover, the organ of Corti
is an avascular organ and the delivery of nutrients depends on gap junction networks to
maintain homeostasis (Chang et al., 2008; Santos-Sacchi and Dallos, 1983). Due to the
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anionic impermeability of Cx30, Cx26 is essential for the movement of important
signaling and metabolic anions: ATP, cAMP, cGMP, IP3, and glutamine within the inner
ear (Zhao, 2005).

1.4 Ototoxicity
Ototoxicity is defined as drug induced toxicity to the inner ear resulting in hearing loss or
vestibular disorders and limits the usage of therapeutic doses of various pharmaceutical
agents (Lanvers-Kaminsky et al., 2017). The inner ear is particularly susceptible to
toxicity because of long-term drug retention as the result of minimal drug elimination
(Breglio et al., 2017; Lanvers-Kaminsky et al., 2017). Ototoxicity related hearing loss
primarily occurs in the high frequency range (2,000-8,000Hz); it is permanent, severe, bilateral, and can severely affect the quality of life of individuals, especially children
(Knight et al., 2005; Langer et al., 2013; Lanvers-Kaminsky et al., 2017; RademakerLakhai et al., 2006; RamShankar et al., 2003). Prevalent ototoxic therapeutics are
aminoglycoside antibiotics and cisplatin, a chemotherapeutic drug (Arslan et al., 1999).
Aminoglycoside antibiotics are used therapeutically to treat gram negative aerobic
bacterial infections and result in ototoxicity in 2-25% of patients (Lanvers-Kaminsky et
al., 2017). For example, aminoglycosides are important in the treatment of bacterial
infections associated with cystic fibrosis in children where risk factors for ototoxicity
include age and cumulative dose of aminoglycosides (Al-Malky et al., 2015). The
mechanism of action of aminoglycosides towards bacteria involves inhibition of the 30S
ribosome, which leads to increased mRNA misreading and prevents protein translation
(Huth et al., 2011). Cisplatin is commonly used in the treatment of solid tumors, and the
incidence of hearing loss in treated patients can be as high as 100% (Kopelman et al.,
1988). Increased risk for cisplatin induced ototoxicity depends on genetics,
environmental factors, and dosing regimen (Dilruba and Kalayda, 2016; Langer et al.,
2013; Lanvers-Kaminsky et al., 2017). The antineoplastic mechanism of cisplatin
consists of cross-linking guanine bases to prevent DNA replication and ultimately leads
to tumor cell death (Langer et al., 2013). In contrast to the normal therapeutic
mechanisms of these ototoxic drugs, they both primarily induce OHC apoptosis in the
high frequency region of the cochlea through the formation of reactive oxygen species
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(ROS) (Callejo et al., 2015; Choung et al., 2009). Aminoglycosides enter hair cells
through the cation MET (mechanoelectrical transduction) channel and to a lesser extent
by endocytosis (Alharazneh et al., 2011; Hashino and Shero, 1995; Huth et al., 2015).
Cisplatin enters hair cells through transporters including the organic cation transporters
(OCT) and copper transporter channels (CTR) (Ciarimboli et al., 2010; Larson et al.,
2009). Other areas of the inner ear can be damaged with increasing doses and
accumulation of these ototoxic therapeutics, such as low frequency OHCs, IHCs, stria
vascularis, and the spiral ganglion neurons (Ciarimboli et al., 2010). The administration
of exogenous antioxidants is effective at reducing ototoxicity (Jo et al., 2019; Kim et al.,
2015; Kim et al., 2016; Sheth et al., 2017). This eludes to the importance of ROS and
antioxidant enzymes in the development of ototoxicity.

1.5 Connexins and the Propagation of Cisplatin Induced Apoptosis
Apoptosis is a key downstream outcome of cisplatin treatment in both cancer cells and
inner ear cells (Garcia-Berrocal et al., 2007; Matsumoto et al., 2016). The amplification
of death signals to neighbouring cells through gap junctions has been shown to increase
apoptosis in a process known as the bystander effect (Dilber et al., 1997). The bystander
effect has been extensively studied in cisplatin-treated cancer cells (Arora et al., 2018;
Dilber et al., 1997; Ding and Nguyen, 2012; Frank et al., 2005; Huang et al., 2001;
Jensen and Glazer, 2004). A diverse range of molecules are capable of travelling through
gap junctions; however, some postulated death signals include ROS, reactive nitrogen
species, calcium, and IP3 (Cusato et al., 2006; Feine et al., 2012; Krysko et al., 2005).
Gap junctions may also allow the transfer of pro-survival signals to damaged
neighbouring cells and facilitate in the dilution of toxic death signals from targeted
cells (Aasen et al., 2019). For example, GJIC protected neighbouring cells when nontumor testicular cells were treated with cisplatin (Hong et al., 2012). In contrast, GJIC
enhanced apoptosis in testicular tumor cells, which demonstrates that the effect of
GJIC may depend on the tissue environment (Hong et al., 2012). Cisplatin becomes a
positively charged molecule once hydrolysed within cells and acts as an electrophile to
form adducts with DNA, RNA, and proteins, such as antioxidant enzymes (LanversKaminsky et al., 2017). Inhibition of antioxidant enzymes by cisplatin has been shown to
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contribute to ROS accumulation (Cetin et al., 2006). Nevertheless, the precise
mechanisms of cisplatin induced ROS accumulation within hair cells are not fully
elucidated. Increased ROS and DNA adducts can activate the intrinsic mitochondrial
apoptosis pathway involving the Bcl-2 protein family (Matsumoto et al., 2016). The
balance between the anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bax is a
key regulator in the responsiveness to apoptotic stimuli (Siddiqui et al., 2015). Bcl-2
prevents Bax oligomerization, which inhibits the re-localization of Bax from the
cytosol to the mitochondria (Siddiqui et al., 2015; Wang et al., 2004). Inactivation or
downregulation of Bcl-2 allows Bax to change conformation and create a pore within
the mitochondria that permits the subsequent release of cytochrome c (Siddiqui et al.,
2015; Wang et al., 2004). Next, caspase-9 and caspase-3 proteases become activated
after they are cleaved and they induce the cleavage of essential proteins causing
irreversible cell death (Brunelle and Letai, 2009; Garcia-Berrocal et al., 2007; Wang et
al., 2004). The involvement of caspase activation in cisplatin induced ototoxicity is
further supported by reduced hair cell loss when caspases are inhibited (Wang et al.,
2004). Connexins have also been found to play GJIC-independent roles in the
progression of apoptosis (Leithe et al., 2018; Naus and Laird, 2010). The carboxy
terminus of Cx43 has over 30 binding partners that are involved in a diverse array of
signaling cascades, including the mitochondrial apoptosis pathway (Leithe et al., 2018;
Naus and Laird, 2010). Cx43 has been reported to be able to interact with Bax and
trans-locate to the mitochondria to facilitate the progression of the mitochondrial
apoptotic pathway in pancreatic cancer cells (Sun et al., 2012).

1.6 Cisplatin Induced ER Stress
Cisplatin also acts through a DNA independent mechanism by activating ER stress in
enucleated cells (Mandic et al., 2003). The ER is important for protein folding,
calcium homeostasis, post-translation modifications, and the secretory pathway
(Mandic et al., 2003). Physiological stressors can result in the accumulation of
unfolded proteins within the ER resulting in ER stress (Gorman et al., 2012). Moderate
ER stress can be resolved through a process known as the unfolded protein response
(Gorman et al., 2012; Xu et al., 2014). Unfolded proteins within the ER lumen cause

7

the dissociation of the binding immunoglobulin protein (BiP) chaperone protein from
ER transmembrane receptors, allowing for receptor activation of downstream
pathways (Malhotra and Kaufman, 2007). These downstream pathways involve the
activation of pro-survival transcription factors and upregulation of chaperone proteins
to re-establish ER homeostasis (Gorman et al., 2012; Shi et al., 2016). BiP have been
found to be upregulated after cisplatin treatment as a mechanism for cisplatin
resistance in cancer cells (Shi et al., 2016). In contrast, proapoptotic mediators can be
activated once ER stress becomes too severe and prolonged (Xu et al., 2014). For
example, the proapoptotic transcription factor C/EBP homologous protein (CHOP)
becomes activated even in the presence of elevated levels of BiP (Xu et al., 2014).
CHOP downregulates Bcl-2, which contributes to apoptosis progression (McCullough
et al., 2001). ER stress can also contribute to the execution of apoptosis through
caspase-3 activation (Rao et al., 2002). This demonstrates an interaction between the
mitochondrial and ER stress induced apoptotic pathways (Wei et al., 2001). Both
apoptotic pathways were activated after cisplatin treatment in rat cochlear cells and
may contribute to the development of ototoxicity (Zong et al., 2017). More research is
needed to determine whether connexins and GJIC play a role in the development and
progression of apoptosis in relation to ototoxicity especially in a tissue-relevant
context.

1.7 GJB2 Mutations Involved in Hearing Loss
A major cause of hearing loss can also be attributed to mutations in the GJB2 gene
encoding for Cx26. Nearly half of all inherited non-syndromic hearing loss is attributed
to mutations in the GJB2, which occurs in ~1/2000 births (Chan and Chang, 2014). The
degree of hearing loss can range from mild to profound; however, the relationship
between genotype and severity of hearing loss is still not fully elucidated (Snoeckx et al.,
2005). Around ~135 different Cx26 mutations that result in hearing loss have been
identified and are predominantly recessive non-syndromic mutations (Fig. 1.1)
(Kenneson et al., 2002; Laird et al., 2017). Non-syndromic Cx26 mutations only result in
hearing loss as a consequence. Syndromic Cx26 mutations produce hearing loss in
addition to a skin disorder and are inherited in a dominant fashion (Srinivas et al., 2018).
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Figure 1.1. Diagram of Cx26 and Cx30 localization within the organ of Corti and
hearing loss linked Cx26 mutations. The organ of Corti within the cochlea has two
distinct gap junction networks composed of Cx26 and Cx30: the epithelial and connective
tissue networks. Cx26 polypeptide sequence is highlighted to show the location of
hearing loss linked Cx26 mutations in red. Hair cell loss is a consequence of Cx26
mutations and contributes to the development of hearing loss. Figure obtained with
permission from Laird et al., 2017.
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The skin is primarily targeted because of the high expression of Cx26 in the epidermis,
which appears to be necessary for keratinocyte differentiation (Lucke et al., 1999; Scott
et al., 2012). These skin disorders include but are not limited to keratitis-ichthyosisdeafness syndrome (KIDS), Bart-Pumphrey syndrome, Vohwinkel syndrome, and
palmoplantar keratoderma (PPK) (Richard, 2005; Srinivas et al., 2018). Within the
polypeptide chain of Cx26, syndromic mutations causing skin phenotypes tend to arise in
the amino terminus and first extracellular loop (de Zwart-Storm et al., 2008). The
syndromic mutant S183F results in palmoplantar keratoderma, yet it is uniquely
localization in the second extracellular loop (de Zwart-Storm et al., 2008). The most
frequent hearing loss linked Cx26 mutation is 35delG, which results in an early
truncation of the Cx26 protein (Chan and Chang, 2014). The carrier rate for 35delG is
1.5% worldwide but is most commonly found in Western and European countries (Chan
and Chang, 2014; Tsukada et al., 2015). However, some countries have a very low
35delG carrier rate emphasizing that other mutations are prevalent in particular regions of
the world due to founder effects (Chan and Chang, 2014; Ohtsuka et al., 2003;
RamShankar et al., 2003). For example, 235delC is the most common GJB2 mutation in
East Asia but the 35delG mutation is very uncommon (Chan and Chang, 2014; Tsukada
et al., 2015).

1.8 Loss- and Gain-of-Function Properties of Cx26 Mutants
Hearing loss linked Cx26 mutations can be categorized by having loss-of-function or
gain-of-function properties; interestingly both properties can be displayed by the same
mutant (Kelly et al., 2015; Srinivas et al., 2018). Loss-of-function connexin mutations
can result in defective Cx26 mutant trafficking to the plasma membrane, acquiring an
abnormal interactome, mutant misfolding, improper docking of mutant containing
connexons, and the formation of non-functional hemichannels and/or gap junctions
(Fig.1.2) (Kelly et al., 2015; Laird et al., 2017). For example, the 35delG mutation results
in an early truncation of Cx26, rendering it non-functional and is considered a loss-offunction mutation (Kelly et al., 2015). Additionally, many non-syndromic Cx26 mutants
are retained in intracellular compartments such as the ER or Golgi apparatus, including:
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Figure 1.2. Mechanisms of connexin mutants that generate disease. Connexin
mutants such as hearing loss linked Cx26 mutants can display loss-of-function or gain-offunction properties. Loss-of-function properties include defective trafficking of the
connexin mutant, formation of a dead hemichannel or gap junction, and defective
interactome and turnover. Gain-of-function properties include aberrant oligomerization of
the connexin mutant, formation of hyperactive or leaky hemichannels, and transdominant interaction of connexin mutant with other connexin isoforms. Figure obtained
with permission from Laird et al., 2017.
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Y155X, S199F, R184Q, and L205P (Ambrosi et al., 2013; Martinez et al., 2009; Su et al.,
2010; Xiao et al., 2011). In general, loss-of-function Cx26 mutations inhibit the passage
of important molecules and metabolites in the cochlea, which impacts cochlear function
and vitality contributing to hearing loss (Martinez et al., 2009). Gain-of-function
connexin mutants may interact with generally noncompatible connexin isoforms, bind
new interactome members, alter connexin half-life, and increase hemichannel and/or gap
junction permeability (Fig.1.2) (Kelly et al., 2015; Laird et al., 2017). Gain-of-function
properties are generally associated with syndromic Cx26 mutants which acquire the
ability to interact and exert a trans-dominant inhibitory effect on other connexin isoforms
expressed in the epidermis (Press et al., 2017; Srinivas et al., 2018). For example, the
syndromic Cx26 mutant, N54K, is associated with Bart-Pumphrey syndrome and
acquired a trans-dominant negative effect on Cx30 and Cx43 gap junction plaque
formation in HeLa cells (Press et al., 2017). Additionally, dominant Cx26 mutants with
gain-of-function properties may exert a dominant negative effect on wild-type Cx26
trafficking and function within the inner ear (Zhang et al., 2011). Though the localization
and function of many Cx26 linked hearing loss mutants have been characterized, many
Cx26 mutants remain to be studied especially in a tissue-relevant context. Furthermore,
due to the diversity and magnitude of different hearing loss linked Cx26 mutations, a
complete understanding of the possible mechanisms of hearing loss are not fully
elucidated.

1.9 Differentiation of Hair Cells and Supporting Cells in the
Developing Organ of Corti
The development of the cochlea is a very intricate and highly organized process
involving many regulatory genes and transcription factors (Basch et al., 2016). Proper
developmental coordination and mosaic patterning of supporting cells around IHCs and
OHCs is essential for hearing (Fritzsch et al., 2011). The inner ear originates from the
ectoderm derived otic placode, which contains pro-sensory progenitor cells destined to
become both supporting cells and hair cells in the organ of Corti (Wu and Kelley, 2012).
Sox2 is a critical transcription factor expressed in the pro-sensory domain that develops
into the organ of Corti (Liu et al., 2018). Sox2 expression becomes restricted to
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supporting cells as development of the inner ear advances and is downregulated in cells
destined to be hair cells (Liu et al., 2018; Puligilla and Kelley, 2017). Pro-sensory
progenitor cells undergo terminal mitosis based on the expression of cell cycle inhibitor
p27Kip1 (Chen and Segil, 1999). The pro-sensory progenitor cells then proceed to
differentiate in a spatial pattern into at least four types of supporting cells and hair cells
(Chen and Segil, 1999). Hair cell specification is initiated by the expression of a basic
helix-loop-helix transcription factor Atoh1 and is additionally important for hair cell
survival only in late embryonic stages (Bermingham et al., 1999; Chonko et al., 2013).
Conversely, the overexpression of Atoh1 results in an overproduction of hair cells
derived from epithelial cells in the immature inner ear (Woods et al., 2004; Zheng and
Gao, 2000). Supporting cell specification involves lateral inhibition involving Notch
signalling, whereby pro-sensory cells adjacent to hair cells are inhibited from forming
into hair cells (Fritzsch et al., 2011; Lanford et al., 2000). Distinct genes are expressed
in different types of supporting cells within the mature organ of Corti (Wan et al.,
2013). For example, Prox1 transcription factor is initially expressed in developing
supporting cells then is solely expressed in outer pillar cells and Deiter’s cells to aid in
proper morphology (Bermingham-McDonogh et al., 2006). Markers of mature hair
cells include unconventional myosin proteins, transcription factor Pou4f3, calcium
binding proteins, and prestin, which are all required for hair cell survival and function
(Hasson et al., 1995; Liu et al., 2014; Xiang et al., 1998; Zheng et al., 2000).
Unconventional myosin proteins are highly expressed in hair cells and their stereocilia,
which are rich in actin filaments (Liu et al., 2014; Steel and Kros, 2001). Therefore,
defects in myosin VIIa and other myosin proteins results in disorganized stereocilia
and induces hearing loss (Hasson et al., 1995; Liu et al., 2014; Steel and Kros, 2001).
Additionally, calcium binding proteins such as calretinin and calsequestrin, play an
important role in regulating calcium levels within hair cells to maintain hair cell
responsiveness (Slepecky and Ulfendahl, 1993).

1.10 The Role of Connexins in Cochlear Development
GJIC is important for the coordination of differentiation throughout inner ear
development (Zhu et al., 2015; Zong et al., 2016). Cx26 conditional knockout mice
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lack the space under the tectorial membrane and a tunnel of Corti (Chen et al., 2018;
Inoshita et al., 2014; Wang et al., 2009; Zhu et al., 2015). This provides evidence that
Cx26 is important in the regulation of supporting cell differentiation and facilitates in
the correct timing for apoptosis. Formation of ribbon synapses within IHCs is
defective and OHCs are deformed in conditional Cx26 knockout mice (Anzai et al.,
2015; Chang et al., 2015). The epithelial gap junction network forms around
embryonic day 16 in the developing mouse cochlea and the connective tissue network
is fully formed at birth (Cohen-Salmon et al., 2002; Frenz and Van De Water, 2000;
Xia et al., 1999). Cx43 is additionally expressed within the developing epithelial cells
of the organ of Corti in mice (Cohen-Salmon et al., 2004). Cx43 is the most
ubiquitously expressed connexin isoform in the body and is important in embryonic
development (Yancey et al., 1992). However, Cx43 expression is absent from the gap
junction networks of the mature cochlea and is limited to the structures composed of
bone (Cohen-Salmon et al., 2004; Kim et al., 2013). Improper supporting cell
differentiation has been linked to disruptions in miRNA communication (Zhu et al.,
2015). Gene expression can be regulated by miRNAs, which have been shown to
transverse Cx26 gap junction channels (Zhu et al., 2015; Zong et al., 2016). A
reduction in important signalling molecules and nutrients has also been implicated in
improper cochlear development and contributes to postnatal cellular degradation of the
inner ear in conditional Cx26 null mouse models (Chang et al., 2015; Sun et al., 2009).
Postnatal cellular degradation of hair cells, supporting cells, and spiral ganglion
neurons occurs as a secondary hearing loss mechanism to improper cochlear
development (Anzai et al., 2015; Liang et al., 2012; Sun et al., 2009). The importance
of Cx26 in cochlear development is further supported by developmental abnormalities
of the organ of Corti in mutant mice expressing the dominant Cx26 mutant R75W
(Inoshita et al., 2008). In the human context, a patient with a syndromic Cx26 mutation
resulting in the skin disorder KIDS also had cochlear development abnormalities
(Griffith et al., 2006). Overall, the role of inner ear connexins and GJIC in the
development of supporting cells and hair cells is still unclear, primarily the underlying
mechanisms involved in disrupted development.
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1.11 Hypothesis
My thesis tests two central hypotheses that are presented in the two separate chapters.
The first chapter encapsulates the hypothesis that the connexin status and gap junctional
intercellular communication (GJIC) affects the sensitivity of HEI-OC1 cochlear cells to
commonly used ototoxic therapeutics. To test this hypothesis, we generated Cx43
deficient HEI-OC1 cells (Cx43 KO) that have decreased GJIC. These cells are derived
from the epithelium of the organ of Corti in mice (Kalinec et al., 2003) and were used to
investigate whether connexin expression and GJIC influenced HEI-OC1 cell sensitivity to
the ototoxic therapeutics: aminoglycoside antibiotics and cisplatin. Additionally, whether
Cx43 expression and GJIC influenced the apoptotic pathways leading to cisplatin induced
cell death was studied.
The second chapter focuses on the hypothesis that hearing loss linked Cx26 mutants exert
distinct hearing loss mechanisms and GJIC influences the differentiation capacity of HEIOC1 cochlear cells. Cx43 KO HEI-OC1 were utilized to analyze the intracellular
localization and function of hearing loss linked Cx26 mutants. These mutants included
two dominant syndromic mutants (N54K and S183F) and two recessive non-syndromic
mutants (R32H and R184P). The capacity of both wild-type and Cx43 KO HEI-OC1 cells
to differentiate into hair cell-like cells expressing hair cell molecular markers prestin,
myosin VIIa, and calsequestrin was investigated.

1.12 Objectives
The objectives for this study were to:
1. Characterize the expression and functional status of connexins in HEI-OC1 cells.
2. Determine if connexin-competent HEI-OC1 cells have differential sensitivity to
cell death upon treatment with cisplatin and aminoglycoside antibiotics.
3. Express and characterize the localization and function of hearing loss linked Cx26
mutants in the absence and presence of wild type connexins.
4. Assess the consequence of GJIC on the differentiation of HEI-OC1 cells into hair
cell-like cells.
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Chapter 2
2 Connexins and gap junctional intercellular communication
alters downstream apoptotic pathways but do not influence
susceptibility of HEI-OC1 cells to ototoxicity
2.1 Introduction
Ototoxicity is a severe dose limiting side effect resulting after cisplatin and
aminoglycoside antibiotic administration (Arslan et al., 1999). Ototoxicity is defined as
inner ear toxicity that results in hearing loss or vestibular irregularities and can impact
quality of life, especially in children (Knight et al., 2005; Lanvers-Kaminsky et al.,
2017). The cochlea contains the sensory organ for hearing, which is known as the organ
of Corti. The organ of Corti contains inner hair cells (IHC) and outer hair cells (OHC)
that are surrounded by the supporting cells that maintain hair cell homeostasis (Wan et
al., 2013). Cisplatin and aminoglycoside antibiotics accumulate within the cochlea and
are capable of entering mechanosensory hair cells (Alharazneh et al., 2011; Breglio et al.,
2017; Ciarimboli et al., 2010; Lanvers-Kaminsky et al., 2017). Cisplatin is a commonly
used chemotherapeutic for the treatment of solid tumors (Langer et al., 2013).
Aminoglycoside antibiotics are used for the treatment of gram-negative bacterial
infections by inhibiting bacteria protein translation (Lanvers-Kaminsky et al., 2017). Hair
cell apoptosis attributed to the overproduction of reactive oxygen species (ROS) is a
common pathological mechanism of both ototoxic therapeutics. ROS overproduction may
be the result of antioxidant enzyme inhibition or dysfunction of cellular respiration
induced by ototoxic therapeutics (Cetin et al., 2006; Lanvers-Kaminsky et al., 2017; Sha
and Schacht, 1999). Cumulative administration of both ototoxic therapeutics can further
disrupt the stria vascularis and spiral ganglion neurons (Cardinaal et al., 2000). Yet, the
exact mechanisms involved in the development of ototoxicity are not fully elucidated.
Cochlear function highly depends on the recirculation of potassium ions (K+) into the
endolymph fluid, which bathes hair cells in order to maintain a high endocochlear
potential (Kikuchi et al., 2000). Gap junction networks composed of connexin proteins
have been implicated in maintaining the endocochlear potential so that hair cell
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stimulation can occur in response to sound (Jagger et al., 2010; Kikuchi et al., 2000).
Connexins are transmembrane domain proteins that oligomerize into hexameric
structures known as connexons (Goodenough and Paul, 2009). Connexons can function
as hemichannels at the cell surface or can dock with another connexon on an adjacent cell
to form a gap junction channel (Laird, 2006). Twenty-one connexin isoforms exist in the
human body (Sohl and Willecke, 2004). Connexin 26 (Cx26) and Cx30 are the main
isoforms expressed in gap junction networks that exist between supporting cells and cells
along the cochlear lateral wall (Forge et al., 2003; Liu et al., 2009). Ions and metabolites
<1 kDa can pass through gap junctions in a process known as gap junctional intercellular
communication (GJIC) (Alexander and Goldberg, 2003). Gap junction networks are
important in delivering nutrients to avascular regions of the cochlea and maintaining
cellular homeostasis (Chang et al., 2008; Santos-Sacchi and Dallos, 1983). After cisplatin
treatment of cancer cells, GJIC facilitates death signal propagation to neighbouring cells
in a process known as the bystander effect (Arora et al., 2018; Huang et al., 2001; Jensen
and Glazer, 2004). These death signals may include calcium, IP3, ROS, and reactive
nitrogen species (Cusato et al., 2006; Feine et al., 2012; Krysko et al., 2005).
Enhancement of GJIC increased apoptosis in cancer cells, and conversely the impediment
of GJIC decreased apoptosis in cochlear-derived cells treated with a low dose of cisplatin
(Aasen et al., 2016; Kim et al., 2014). Surprisingly, even though connexins have a
prominent role in hearing and are abundantly expressed in the cochlea, it is unknown
whether they are involved in the development of ototoxicity.
The mitochondrial apoptosis pathway is involved in cisplatin induced hair cell death
(Callejo et al., 2015). Intrinsic stressors can activate this pathway, including ROS and
DNA adducts created by cisplatin (Garcia-Berrocal et al., 2007; Matsumoto et al., 2016).
The ratio between the pro-apoptotic protein Bax and anti-apoptotic protein Bcl-2 is an
indicator of apoptotic potential (Siddiqui et al., 2015). Bax escapes the inhibitory effect
of Bcl-2 when Bcl-2 is downregulated or inhibited. This subsequently leads to Bax
oligomerization and pore formation in the mitochondrial outer membrane. Cytochrome c
is then able to exit the mitochondria and lead to the activation of downstream caspases
(Siddiqui et al., 2015; Wang et al., 2004). Cleaved caspase-3 (CC3) cleaves proteins
essential for cell survival and therefore is the terminal executor of apoptosis (Brunelle
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and Letai, 2009; Garcia-Berrocal et al., 2007). The endoplasmic reticulum (ER) stress
pathway is also activated by cisplatin and can contribute to caspase-3 activation (Mandic
et al., 2003; Rao et al., 2002). Moderate ER stress can be resolved through the activation
of the unfolded protein response (Gorman et al., 2012; Xu et al., 2014). ER stress is
activated by an increase in unfolded proteins within the ER lumen resulting in binding
immunoglobulin protein (BiP), a chaperone protein, dissociation from ER transmembrane
receptors (Malhotra and Kaufman, 2007). These receptors when activated lead to
downstream signalling cascades that induce the upregulation of BiP and other chaperone
proteins to re-establish ER homeostasis (Gorman et al., 2012; Shi et al., 2016). If ER
stress becomes too severe and is prolonged, apoptosis is activated (Rao et al., 2002; Xu et
al., 2014). GJIC-independent mechanisms are capable of influencing apoptotic pathways
(Leithe et al., 2018; Naus and Laird, 2010). Specifically, the cytoplasmic tail of Cx43 has
been implicated in the initiation of the mitochondrial apoptotic pathway by facilitating
Bax translocation to the mitochondria (Sun et al., 2012). Nevertheless, the role of
connexins and GJIC in cisplatin induced apoptosis is not fully elucidated.
In this study, we investigated whether connexins and GJIC influence the susceptibility of
HEI-OC1 cochlear-derived cells to cell death after treatment with ototoxic therapeutics.
HEI-OC1 cells are an immortalized cell line derived from the region associated with the
epithelium of the organ of Corti in cochlear explants of P7 mice. These cells were
collected using the limiting dilution method and were characterized as a common
progenitor to supporting cells and hair cells. HEI-OC1 cells have been shown to
differentiate into cells expressing hair cell markers when cultured under non-permissive
conditions (Kalinec et al., 2003). HEI-OC1 cells have been previously utilized as a tissuerelevant in vitro model to study the development of ototoxicity (Jia et al., 2018; Kalinec
et al., 2016; Kim et al., 2015; Kim et al., 2014). Surprisingly, HEI-OC1 cells lack the
expression of in vivo connexin isoforms: Cx26 and Cx30; however, HEI-OC1 cells
abundantly express Cx43. We ablated Cx43 from HEI-OC1 cells (Cx43 KO) using
CRISPR-Cas9 technologies to generate cochlear cells with greatly reduced GJIC. Wild
type (WT) and Cx43 KO HEI-OC1 cells were not sensitive to aminoglycoside antibiotics
but had decreased cell viability when treated with cisplatin. Cx43 KO HEI-OC1 cells had
increased antioxidant enzyme mRNA expression and ER stress related BiP protein
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expression after cisplatin treatment. The mitochondrial apoptotic pathway involving Bax
was predominately activated in cisplatin treated WT HEI-OC1 cells. Overall, a lack of
connexin expression and GJIC did not alter the susceptibility of HEI-OC1 cells to
ototoxic therapeutics but may have altered the downstream pathways leading to apoptosis
when treated with cisplatin.

2.2 Materials and Methods
2.2.1 Cell Culture and Reagents
House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were kindly provided by Dr.
Kalinec (House Ear Institute, Los Angeles, CA). HEI-OC1 cells were grown in high
glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Cat# 1190-044, Life
Technologies) supplemented with 10% fetal bovine serum and 2mM L-glutamine and
incubated in permissive conditions (33°C, 10% CO2). To study cisplatin induced cell
death, permissive HEI-OC1 cells were treated with various doses of cisplatin (Cat#
PHR1624, Sigma-Aldrich) or saline as a vehicle control for 48 hours.

2.2.2 Generation of Cx43 Knockout HEI-OC1 Cells Using CRISPR-Cas9
Cx43 was functionally ablated from HEI-OC1 cells using a pSpCas9(BB)-2A-GFP
(PX458) vector obtained from Addgene (Cat# 48138) encoding human S. pyogenes Cas9
nuclease and EGFP. Two gRNAs were designed using Sanger Institute CRISPR finder
towards GJA1 to generate indels 115 base pairs apart (base pairs 59-173). The designed
gRNAs consisted of Sanger gRNA ID 324658622 (forward, 5’CGCTGTAACACTCAACAACC; reverse, 5’-GGTTGTTGAGTGTTACAGCG) and ID
324658605 (forward, 5’- AAGCCTACTCCACGGCCGGA; reverse, 5’TCCGGCCGTGGAGTAGGCTT) and Bbsl digestion sites were added to each pair of
oligonucleotides. Each phosphorylated and annealed gRNA was cloned into Bbsl
digested vectors. HEI-OC1 cells were transfected with 1µg of each gRNA plasmid using
Mirus TransIT-LT1 Transfection Reagent (Cat# MIR2300, Mirus Bio LLC) according to
manufacturer’s instructions. For clonal selection, fluorescence-activated cell sorting
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(FACS) was utilized to select for green fluorescent protein (GFP) expressing cells 48
hours after transfection. Individual clones were screened for Cx43 ablation using Western
blot analysis to identify Cx43 KO HEI-OC1 cells. Two individual Cx43 KO clones were
used for most experiments.

2.2.3 Immunoblotting
HEI-OC1 cells were washed with phosphate-buffered saline (PBS) and lysed using 1x IP
lysis buffer ((2x IP lysis buffer (2 % Triton X-100, 330mM NaCl, 20mM Tris, 2mM
EDTA, 2mM EGTA, 1 % NP-40, pH 7.4), a complete mini protease inhibitor cocktail
tablet (Cat# 11836153001, Roche Diagnostics), 1:100 NaF and 1:100 Na3VO4
phosphatase inhibitors) diluted in PBS). Protein concentrations were measured using
bicinchoninic acid assays. Equal amounts of protein were separated using SDS-PAGE
(10% or 12% polyacrylamide gel) and were transferred to a nitrocellulose membrane
using an iBlot transfer system. Membranes were blocked with 3% bovine serum albumin
(BSA) dissolved in PBS Tween (0.05% Tween 20) (PBST) for two hours and were
probed overnight with primary antibodies in 3% BSA + PBST, unless indicated
otherwise. Primary antibodies included: mouse anti-GAPDH (1:5000, Cat# MAB374,
EMD Millipore), rabbit anti-GAPDH (1:5000, Cat# G9545, Sigma), rabbit anti-Cx43
(1:750, Cat# C6219, Sigma), mouse anti-Cx26 (1:1000, Cat# 138100, Life
Technologies), rabbit anti-Cx30 (1:750, Cat# 712200, Life Technologies), rabbit anti-Bax
(dissolved in Tris buffered saline tween (TBST), 1:1000, Cat# 2772, Cell Signaling), and
rabbit anti-BiP (1:1000, Cat# G8918, Sigma Aldrich). Membranes were then washed with
PBST and incubated with Alexa Fluor 680-conjugated anti-rabbit-IgG secondary
antibody (1:5000, Cat# A21057, Life Technologies) and IRdye800-conjugated antimouse-IgG antibody (1:5000, Cat# 611-132-002, Rockland) for one hour. Protein signals
were then visualized using an Odyssey infrared imaging system (LiCor) and the intensity
of the bands were quantified using Odyssey software. Protein expression was normalized
to the loading control GAPDH. One-way analysis of variance (ANOVA) statistical tests
were used to compare protein expression between different treatments within WT or
Cx43 KO HEI-OC1 cells and two-way ANOVAs were used to compare protein
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expression of different treatments between WT and Cx43 KO HEI-OC1 cells. Both were
followed by a Tukey’s post hoc test.

2.2.4 Immunofluorescent Labelling
HEI-OC1 cells were grown on glass coverslips and were fixed with 4%
paraformaldehyde (PFA) for 10 minutes, washed with PBS, blocked and permeabilized
with 3% BSA + 0.1% Triton X-100 for one hour. Coverslips were incubated with the
desired primary antibodies diluted in 3% BSA + 0.1% Triton X-100 overnight at 4°C,
unless indicated otherwise. Primary antibodies included: rabbit anti-Cx43 (1:750, Cat#
C6219, Sigma), mouse anti-Cx26 (1:200, Cat# 138100, Life Technologies), rabbit antiCx30 (1:200, Cat# 712200, Life Technologies), rabbit anti-CC3 (1:1000 two-hour
incubation, Cat# C8487, Sigma Aldrich), mouse anti-protein disulfide isomerase (PDI)
(Cat# SPA-891, Assay Designs), and rabbit anti-BiP (1:1000). Coverslips were then
incubated with secondary antibodies for two hours at room temperature. Secondary
antibodies included: donkey anti-rabbit Alexa Fluor 488 (Cat# A21206, Invitrogen), goat
anti-rabbit Alexa Fluor 568 (Cat# A11036, Invitrogen), and goat anti-mouse Alexa Fluor
555 (Cat# A21422, Invitrogen). Alexa Fluor 488 Phalloidin (1:400, Cat# A12379,
Invitrogen) was used to detect the actin cytoskeleton. Nuclei were then stained with
Hoechst (1:1000 diluted in distilled H2O, Cat# H3570, Molecular Probes) for ten
minutes. Organotypic cochlear cultures were dissected and immunolabelled as previously
described (Kelly et al., 2019). Coverslips were mounted using Airvol and
immunofluorescent images were taken using a LSM800 Zeiss confocal microscope
equipped with airyscan. The percentage of cells expressing CC3 was quantified by
counting the number of red cells and dividing by the total number of nuclei in a blinded
fashion. Four separate images were captured per coverslip, which generated 16 images
per experimental group after four biological replicates. Percentage of cells expressing
CC3 was analyzed using a two-way ANOVA followed by a Tukey’s post hoc test.

2.2.5 Scrape Loading Dye Transfer Assay
HEI-OC1 cells were seeded onto culture dishes that were coated with sterile filtered type
I rat tail collagen (Cat# 354236, Corning Life Sciences) diluted in 0.02 M acetic acid for
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one hour. HEI-OC1 cells were washed two times with Hank’s balanced salt solution
(HBSS) once the cells were 80% confluent, then cells were scraped at three different
locations on the dish. Cells were then incubated with neurobiotin (2mg/ml, Cat# SP1120, Vector), a gap junction permeable molecule (287 Da, charge +1), and with a gap
junction impermeable dye dextran rhodamine (0.5mg/ml, Cat# D1824, Invitrogen) for
five minutes at 33°C 10% CO2. Cells were then washed with HBSS and fixed for ten
minutes with 4% PFA. Cells were solubilized using 0.1% Triton X-100 for 30 minutes,
before an hour incubation with Alexa Fluor 488- conjugated streptavidin (1:1000, Cat#
S11223, Invitrogen) to visualize neurobiotin. Samples were imaged using airyscan on a
Zeiss LSM 800 confocal microscope equipped with a 10x objective. In three independent
experiments, a minimum of six images were taken per experiment and four
measurements per image were collected for a total of at least 72 individual
measurements. ImageJ was used to measure the distance of neurobiotin spread (µm) after
the first row of damaged cells along the scrape and an unpaired t-test was performed.

2.2.6 Fluorescence Recovery After Photobleaching (FRAP)
HEI-OC1 cells were seeded onto 35mm glass bottom dishes coated with sterile filtered
type I rat tail collagen. Once cells were 100% confluent and were forming cell-cell
contacts, cells were incubated with HBSS containing 1µl/ml calcein-AM (Cat# C3100MP, Invitrogen) for five minutes. Cells were then washed with HBSS and replenished
with fresh media. Cells were placed in an incubation chamber over a LSM800 Zeiss
confocal microscope set at 33°C and 10% CO2. A selected cell (region of interest (ROI))
with cell-cell contacts was photobleached to <30% of initial intensity. An image was
captured every 10 seconds over three minutes using a 63x oil immersion objective and
dye recovery was analyzed using the Time Series Analyzer V3 plugin on ImageJ. For
each ROI, fluorescence recovery was measured using Recovery (%) = (Ft − F0/Fb) x 100
(Ft fluorescence at each time point after photobleaching, F0: fluorescence at 0 s after
photobleaching, Fb: fluorescence before photobleaching) (Kim et al., 2014). Fluorescence
recovery was then plotted over time for three independent experiments each composed of
six replicates and the area under the curve (AUC) was calculated. AUC data was
analyzed using an unpaired t-test.
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2.2.7 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted from WT and two independent Cx43 KO clones using RNeasy
Mini Protocol for Isolation of Total RNA from Animal Cells (Cat# 74106, Qiagen) and
converted to cDNA using the High Capacity cDNA Reverse Transcription Kit
(Cat#4368814, Applied Biosystems). qRT-PCR was performed using PowerUp SYBR
Green Master Mix (Cat# A25742, Life Technologies) and the cycle conditions for each
primer consisted of: 50°C for 2 min, 95°C for 2 min, 95°C for 5 s, 60°C for 15 s for 40
cycles, followed by a melt curve. The following primers were used: 18s rRNA, the house
keeping gene (forward, 5’-GTAACCCGTTGAACCCCATT; reverse, 5’CCATCCAATCGGTAGTAGCG), manganese superoxide dismutase (MnSOD)
(forward, 5’- GGCCAAGGGAGATGTTACAA; reverse, 5’CCTTGGACTCCCACAGACAT), glutathione peroxidase (GPx1) (forward, 5’ GTCCACCGTGTATGCCTTCT; reverse 5’ -CCTCAGAGAGACGCGACATT),
catalase (forward, 5’- GGAGGCGGGAACCCAATAG; reverse, 5’GTGTGCCATCTCGTCAGTGAA, Bcl-2 (forward, 5’ –
CCTGTGGATGACTGAGTACC; reverse, 5’-GAGACAGCCAGGAGAAATCA), and
Bax (forward, 5’ – GTTTCATCCAGGATCGAGCA; reverse, 5’CATCTTCTTCCAGATGGTGA). mRNA levels were normalized to 18s rRNA and
measured using the ∆∆CT method. mRNA expression was statistically analyzed using a
one-way ANOVA to compare mRNA expression between different treatments within WT
or Cx43 KO HEI-OC1 cells and two-way ANOVA was used to compare mRNA
expression of different treatments between WT and Cx43 KO HEI-OC1 cells. Both were
followed by a Tukey’s post hoc test.

2.2.8 WST-1 Cell Viability Assay
Cell viability of WT and two independent Cx43 KO clones was analyzed using WST-1
assays (Cat# 5015944001, Sigma-Aldrich) where the tetrazolium salt, WST-1, is cleaved
at the cell surface into soluble formazan by only metabolically active cells. HEI-OC1
cells were plated at a density of 1x104 cells/well for aminoglycoside experiments. For
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cisplatin treatment cells were plated at a density of 1x104 cells/well (low density) or
3x104 cells/well (high density) in a 96 well dish and were left overnight to plate in regular
media. HEI-OC1 cells were then treated with the intended concentration of gentamicin
sulfate (Cat# PHR1077, Sigma Aldrich), kanamycin monosulfate (Cat# 400-145-IG,
Multicell), or cisplatin (Cat# PHR1624, Sigma-Aldrich) in triplicate for 24 or 48 hours.
Additionally, organotypic cochlear cultures were treated with 200µM or 2mM of
kanamycin or gentamicin for 24 hours as a positive control for aminoglycoside induced
hair cell death. HEI-OC1 cells were then treated with 1:10 dilution of WST-1 in fresh
media for two hours at 33°C. Wells with no cells and only media were used as a negative
control. The optical density of each sample was measured using a spectrophotometer
reader set at 450nm and a reference wavelength at 630nm. Cell viability was determined
by subtracting the reference absorbance, and the optical density of the negative control
from each sample. Cell viability was then measured as a percentage of the cell viability of
cells treated with saline, denoted as 100%. Two-way ANOVAs followed by Tukey’s post
hoc tests were used for statistical analysis.

2.2.9 Statistical Analysis
All statistical analysis was conducted using Graph Pad Prism 6 and results were indicated
as statistically significant when P< 0.05. Outliers were removed using the ROUT method
with Q set to 1%. Results are presented as mean ± SEM unless stated otherwise.

2.3 Results
2.3.1 HEI-OC1 cells express abundant Cx43 and lack in vivo organ of Corti
connexin isoforms
The connexin profile of HEI-OC1 cells was characterized using protein lysates collected
from both WT and Cx43 KO cells and analyzed using Western blots. WT HEI-OC1 cells
expressed abundant Cx43, while Cx43 was absent from multiple clones of Cx43 KO
HEI-OC1 cells (Fig. 2.1A). Of note, Cx43 is not the prominent Cx isoform expressed in
the in vivo organ of Corti, where Cx26 and Cx30 are abundantly found (Forge et al.,
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2003). Surprisingly, neither Cx26 or Cx30 were expressed in WT or Cx43 KO HEI-OC1
cells and were not upregulated after Cx43 ablation in Cx43 KO HEI-OC1 cells (Fig.
2.1A). Using immunofluorescence microscopy, multiple gap junction plaques composed
of Cx43 were identified in WT cells and some Cx43 was also found intracellularly (Fig.
2.1B). In accordance with our Western blot findings, Cx26 and Cx30 were not detected in
WT or Cx43 KO HEI-OC1 cells (Fig. 2.1B).

2.3.2 Cx43 KO HEI-OC1 cells have greatly reduced gap junctional
intercellular communication
To investigate the consequence of connexin expression and ablation on GJIC, functional
assays utilizing gap junction permeable molecules were conducted. For scrape loading
dye transfer assays, confluent cultures of HEI-OC1 cells were scraped and incubated with
a gap junction permeable positively charged molecule, neurobiotin (287Da). Distance of
neurobiotin spread was analyzed from the first row of damaged cells and on average
travelled 122.3μm in WT cell cultures and 13.4μm in Cx43 KO cell cultures (Fig. 2.2A).
FRAP was also completed to further determine the level of GJIC in HEI-OC1 cells using
a negatively charged gap junction permeable dye calcein-AM (623Da). A selected cell
was photobleached and fluorescent dye recovery within that cell was measured over time
as an indicator of GJIC (Fig. 2.2B). Fluorescence recovery was measured for 170 seconds
after photobleaching and the area under the curve was calculated (Fig. 2.2B). WT HEIOC1 cells had significantly greater dye recovery than Cx43 KO cells (Fig. 2.2B). These
findings demonstrate that the lack of connexin expression in Cx43 KO HEI-OC1 cells
results in greatly reduced GJIC.
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Figure 2.1. Characterization of connexin protein expression in HEI-OC1 cells. (A)
Western blots for Cx43, Cx26, and Cx30 protein expression in WT and Cx43 KO HEIOC1 cells after three subsequent passages of three distinct clones, where mouse cochlear
lysate was used as a positive control. Cx43 was successfully ablated in multiple clones of
Cx43 KO HEI-OC1 cells using CRISPR-Cas9 technology. (A, B) Cx26 and Cx30 protein
expression was absent in both WT and Cx43 KO HEI-OC1 cells. (B) Cx43 was detected
at the plasma membrane in WT HEI-OC1 cells denoted by white arrows and was also
localized intracellularly. Green= phalloidin, blue= Hoechst to stain the nuclei. Scale bar=
10μm.

42

A

WT

B

Unbleached

WT

Cx43 KO

Figure 2.2

Figure 2.2.

Cx43 KO

Bleached

170 Seconds

43

Figure 2.2. Ablation of Cx43 in HEI-OC1 cells greatly reduces gap junctional
intercellular communication. (A) Representative micrographs of a scrape loading dye
transfer assay in WT and Cx43 KO HEI-OC1 cells. Cells were scraped and incubated
with the gap junction permeable tracer neurobiotin (green) and impermeable dextran
rhodamine dye (red). Cx43 KO HEI-OC1 cells exhibited significantly less neurobiotin
transfer from the first row of damaged cells than WT cells (*** P< 0.001). (B)
Representative micrographs of WT and Cx43 KO HEI-OC1 cells loaded with calceinAM and fluorescence recovery after photobleaching of a selected cell (outlined in white).
Dye recovery and area under the curve was measured over 170 seconds. Cx43 KO HEIOC1 cells had significantly reduced dye recovery after photobleaching compared to WT
cells (** P< 0.01). Data represent mean ± SEM from three independent experiments and
were analyzed using an unpaired t-test. Scale bar (A) 100μm and (B) 10μm.
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2.3.3 WT and Cx43 KO HEI-OC1 cells are not sensitive to aminoglycoside
antibiotics
To assess the influence of connexins and GJIC on the incidence of cell death in response
to treatment with ototoxic therapeutics, both WT and Cx43 KO HEI-OC1 cells were
treated with increasing doses of aminoglycoside antibiotics. By ablating Cx43 and greatly
reducing GJIC in HEI-OC1 cells this provided us with an adequate model to study
whether GJIC is involved in the development of ototoxicity. To examine whether Cx43
KO HEI-OC1 cells had differential sensitivity to aminoglycoside antibiotics compared to
WT cells, WST-1 assays were conducted. WST-1 assays utilize the formation of
formazan from WST-1 in metabolically active cells as a measurement of cell viability.
There was no significant decrease in cell viability of WT or Cx43 KO HEI-OC1 cells 24
and 48-hours after treatment with aminoglycoside antibiotics gentamicin and kanamycin,
as compared to saline treatment (Fig. 2.3A, B). Additionally, there was no difference in
susceptibility to cell death between WT and Cx43 KO HEI-OC1 cells after 24 and 48
hours (Fig. 2.3A, B). To determine if gentamicin and kanamycin were indeed capable of
inducing hair cell death as often seen in ototoxicity cases (Choung et al., 2009; Forge,
1985), organotypic cochlear cultures of postnatal mice were treated with both antibiotics
for 24 hours. Treatment with 200μM gentamicin, 2mM gentamicin, and 2mM kanamycin
resulted in hair cell loss evident by the lack of myosin VI immunolabelling (Fig. 2.3C).
Overall, HEI-OC1 cells are not sensitive to aminoglycoside induced cell death in vitro
and reduced GJIC does not influence susceptibility to these antibiotics.

2.3.4 Lack of Cx43 and reduced GJIC did not influence HEI-OC1 cell
susceptibility to cisplatin induced cell death
Since ototoxicity often occurs in patients undergoing chemotherapy we next assessed if
cells derived from the organ of Corti, HEI-OC1 cells, might be differentially sensitive to
cisplatin treatment dependent on the level of GJIC. Interestingly, 24 and 48 hours of
cisplatin treatment greatly reduced WT and Cx43 KO HEI-OC1 cell viability. However,
Cx43 KO cells tolerated low concentrations (10μM) of cisplatin treatment, but this
difference did not persist at higher doses (Fig. 2.4A). Additionally, while high density
cell cultures were more resistant to cisplatin induced cell death potentially due to
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Figure 2.3. Aminoglycoside antibiotics do not decrease HEI-OC1 cell viability. WST1 assays were utilized to determine cell viability. Cell viability was not decreased in
either WT or Cx43 KO HEI-OC1 cells after (A) 24 or (B) 48 hours of gentamicin or
kanamycin treatment. (C) Organotypic cochlear cultures were used as a positive control
for hair cell death after antibiotic treatment. Hair cells were immunolabelled with myosin
VI (red) and were damaged after 24 hours of 200μM gentamicin treatment and exposure
to 2mM of both antibiotics. Scale bar = 20μm. Data represent mean ± SEM from three
independent experiments (Two-way ANOVA, Tukey’s post hoc test).
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Figure 2.4. Cell viability is decreased in WT and Cx43 KO HEI-OC1 cells after 24
and 48-hour cisplatin treatment. WST-1 assays were used to determine cell viability.
(A) After 24 hours of 10μM cisplatin treatment Cx43 KO HEI-OC1 cells had
significantly higher cell viability then WT cells. However, no differences in cell viability
were detected at higher cisplatin concentrations after 24 hours, or when treated with
cisplatin for (B) 48 hours at low and high cell densities. Data represent mean ± SEM
from four independent experiments. (* P< 0.05, two-way ANOVA, Tukey’s post hoc
test).
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increased opportunity for GJIC, there were no notable differences in cell viability in cells
expressing Cx43 (Fig. 2.4B). Thus, the lack of Cx43 and reduced GJIC in Cx43 KO HEIOC1 cells did not provide overt protection from cisplatin-induced cell death.

2.3.5 Antioxidant enzyme mRNA expression increases in Cx43 KO HEIOC1 cells after cisplatin treatment
Cisplatin induced cell death has previously been reported to occur via an intrinsic
pathway involving mitochondrial dysfunction leading to apoptosis (Garcia-Berrocal et
al., 2007). Therefore, various steps along the apoptosis pathway were analyzed to
investigate whether differences occurred between GJIC competent (WT) and GJIC
deficient (Cx43 KO) HEI-OC1 cells. It has been well documented that the formation of
ROS and the depletion of antioxidant enzyme activity are established elements of
ototoxicity in the organ of Corti after cisplatin treatment (Cigremis et al., 2015; Sheth et
al., 2017). To determine whether WT or Cx43 KO HEI-OC1 cells may differ in their
susceptibility to ROS accumulation, the mRNA levels of various antioxidant enzymes
were measured. First, MnSOD was assessed as it is responsible for converting superoxide
into hydrogen peroxide, and then both GPx1 and catalase convert hydrogen peroxide into
water. Cx43 KO HEI-OC1 cells had significantly increased MnSOD mRNA expression
after treatment with 30μM of cisplatin for 48 hours in comparison to WT cells and saline
treated Cx43 KO cells (Fig. 2.5A). The mRNA levels of GPx1 also significantly
increased in Cx43 KO HEI-OC1 cells after treatment with cisplatin for 48 hours (Fig.
2.5B). Furthermore, catalase mRNA was significantly higher in Cx43 KO HEI-OC1 cells
treated with 15μM and 30μM compared to WT cells treated with the same concentrations
of cisplatin (Fig. 2.5C). Additionally, after treatment with 15μM of cisplatin, Cx43 KO
HEI-OC1 cells had increased catalase mRNA expression compared to saline treated Cx43
KO cells (Fig. 2.5C). Cx43 KO HEI-OC1 cells overall had increased mRNA expression
of several antioxidant enzymes after cisplatin treatment in comparison to WT HEI-OC1
cells.
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Figure 2.5. Cx43 KO HEI-OC1 cells have increased mRNA expression of
antioxidant enzymes after cisplatin treatment compared to WT cells. WT and Cx43
KO HEI-OC1 cells were treated with saline, 15μM, or 30μM of cisplatin for 48 hours
before total RNA was collected. (A) Manganese superoxide dismutase (MnSOD) mRNA
expression significantly increased in Cx43 KO HEI-OC1 cells after 30μM of cisplatin
treatment compared to saline treated cells and WT cells. (B) Glutathione peroxidase
(GPx1) mRNA expression significantly increased in Cx43 KO HEI-OC1 cells after
cisplatin treatment. (C) Additionally, after cisplatin treatment catalase mRNA expression
was significantly greater in Cx43 KO HEI-OC1 cells in comparison to WT cells. Two
and three outliers were removed from MnSOD and catalase qPCR data, respectively.
Data represent mean ± SEM from four independent experiments comprised of two
independent Cx43 KO clones (* P<0.05, ** P< 0.01 two-way ANOVA, ★ P< 0.05, oneway ANOVA, Tukey’s post hoc test).
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2.3.6 Pro-apoptotic Bax protein expression is upregulated in WT HEI-OC1
cells treated with cisplatin
As ROS accumulate, mitochondrial dysfunction occurs and evidence suggests that the
ratio between Bax, a pro-apoptotic protein, and Bcl-2, an anti-apoptotic protein increases
to further promote apoptosis (Siddiqui et al., 2015). We found that the ratio between Bax
and Bcl-2 mRNA levels significantly increased in WT and Cx43 KO HEI-OC1 cells
treated with cisplatin (Fig. 2.6A). The protein expression of Bax only increased in WT
HEI-OC1 cells after 15μM of cisplatin treatment and was not upregulated in Cx43 KO
cells after cisplatin treatment (Fig. 2.6B). These findings suggest that WT HEI-OC1 cells
may preferentially induce Bax expression after cisplatin treatment compared to Cx43 KO
HEI-OC1 cells.

2.3.7 Increased cleaved caspase 3 expression in HEI-OC1 cells treated with
cisplatin is independent of Cx43 expression and GJIC
As apoptosis progresses, caspase 3 is cleaved and becomes activated, which is thought to
be an irreversible step towards apoptosis (Brunelle and Letai, 2009). Therefore, cisplatin
treated HEI-OC1 cells were immunolabelled for CC3 to determine if there were any
differences in CC3 expression between WT and Cx43 KO HEI-OC1 cells. Staurosproine
treated cells were used as a positive control for CC3 expression (Fig. 2.7A). After
determining the percentage of cells expressing CC3, both WT and Cx43 KO HEI-OC1
cells had increased CC3 expression after cisplatin treatment for 48 hours (Fig. 2.7B).
Therefore, HEI-OC1 cells are undergoing apoptosis involving CC3 in response to
cisplatin treatment.
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Figure 2.6. Bax/Bcl-2 mRNA expression and Bax protein expression increased in
WT HEI-OC1 cells after cisplatin treatment. (A) Bax/Bcl-2 mRNA ratio was
measured and significantly increased in WT and Cx43 KO HEI-OC1 cells treated with
cisplatin for 48 hours. (B) Bax protein expression was significantly greater in WT cells
after treatment with 15μM of cisplatin compared to saline treated WT cells. Three
outliers were removed from Bax/Bcl-2 qRT-PCR data. Data represents mean ± SEM
from four independent experiments comprised of two independent Cx43 KO clones (**
P< 0.01, *** P< 0.001 two-way ANOVA, ★ P< 0.05, ★★ P< 0.01 one-way AVOVA,
Tukey’s post hoc test).
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Figure 2.7. Cisplatin treatment increases the percentage of WT and Cx43 KO HEIOC1 cells expressing cleaved caspase 3. (A) WT and Cx43 KO HEI-OC1 cells were
immunolabelled for cleaved caspase 3 (CC3) (red) after 48 hours of cisplatin treatment.
Staurosporine treated cells were used as a positive control. (B) The percentage of cells
expressing CC3 significantly increased in both WT and Cx43 KO HEI-OC1 cells after
cisplatin treatment. Blue= Hoechst to stain nuclei, scale bar= 10μm. Data represents
mean ± SEM from four independent experiments comprised of two independent Cx43
KO clones (* P< 0.05, ** P< 0.01, **** P< 0.0001, two-way ANOVA, Tukey’s post hoc
test).
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2.3.8 Cx43 KO HEI-OC1 cells may have increased ER stress after cisplatin
treatment
In addition to cisplatin inducing apoptosis through the mitochondrial pathway, cisplatin
has also been found to promote cell death by generating ER stress (Mandic et al., 2003).
To measure ER stress in WT and Cx43 KO HEI-OC1 cells, we looked at BiP protein
expression, an ER chaperone protein that is upregulated during ER stress. Thapsigargintreated cells were used as a positive control to induce ER stress (Fig. 2.8A). BiP protein
expression was significantly increased in Cx43 KO HEI-OC1 cells treated with 30μM of
cisplatin for 48 hours compared to WT cells and saline-treated Cx43 KO cells (Fig.
2.8A). To further analyze BiP expression and cellular localization, we immunolabelled
WT and Cx43 KO HEI-OC1 cells for BiP after cisplatin treatment. BiP expression
visually appeared to increase after cisplatin treatment and co-localized with PDI, an ER
resident protein (Fig. 2.8B). These results indicate that Cx43 KO HEI-OC1 cells may
experience more ER stress related to cisplatin treatment.
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Figure 2.8. Cx43 KO HEI-OC1 cells have increased BiP protein expression after
cisplatin treatment. WT and Cx43 KO HEI-OC1 cells were treated with saline or
cisplatin (15μM or 30μM) for 48 hours. (A) Binding immunoglobulin protein (BiP)
expression significantly increased in Cx43 KO HEI-OC1 cells treated with 30μM of
cisplatin compared to WT cells, saline and 15μM cisplatin treated Cx43 KO cells.
Thapsigargin treated cells were used as a positive control for ER stress. (B) Cells were
co-immunolabelled for protein disulfide isomerase (PDI), an ER resident protein (red).
Fluorescence intensity of BiP expression increased in cisplatin-treated HEI-OC1 cells
compared to saline-treated cells and BiP was highly localized to the ER. Blue= Hoechst
to stain the nuclei, scale bar= 10μm. One outlier was removed from BiP protein
expression data. Data represents mean ± SEM from four independent experiments
comprised of two independent Cx43 KO clones (* P< 0.05 two-way ANOVA, ★ P< 0.05
one-way AVOVA, Tukey’s post hoc test).
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2.4 Discussion
Gap junction networks composed of Cx26 and Cx30 within the inner ear play a vital role
in hearing by allowing the movement of K+ and maintaining homeostasis (Forge et al.,
2003; Zhao et al., 2006). Connexins can also transfer death signals from apoptotic cells to
adjacent healthy cells to propagate apoptosis (Dilber et al., 1997). This process is known
as the bystander effect, which may be harnessed as a tool for enhancing the efficiency of
chemotherapy to kill tumor cells (Arora et al., 2018; Dilber et al., 1997). Unfortunately,
apoptosis of healthy cells in the inner ear occurs in patients treated with ototoxic
therapeutics leading to hearing loss (Lanvers-Kaminsky et al., 2017). It remains unclear
whether gap junction networks facilitate the development of ototoxicity within the inner
ear or whether modulation of connexin expression could serve as a therapeutic target to
circumvent hearing loss. In this study, we investigated the role of connexins and GJIC in
the susceptibility of HEI-OC1 cochlear cells to cell death after treatment with ototoxic
therapeutics: aminoglycoside antibiotics and cisplatin. We found that the lack of
connexin expression and reduction of GJIC did not protect HEI-OC1 cells from cisplatin
induced cell death. However, the apoptotic pathways leading to apoptosis in cisplatin
treated HEI-OC1 cells were altered depending on their connexin and GJIC status.
Surprisingly, HEI-OC1 cells were not sensitive to aminoglycoside antibiotics; therefore
HEI-OC1 cells may not be an appropriate model to study aminoglycoside induced
ototoxicity in vitro.
HEI-OC1 cells were derived from the epithelial region of the organ of Corti in mouse
cochlear explants. These cells resemble a common progenitor to supporting cells and hair
cells (Kalinec et al., 2016; Kalinec et al., 2003). We observed that Cx43 is abundantly
expressed in WT HEI-OC1 cells. To circumvent the fact that Cx43 is not commonly
found in the organ of Corti, we ablated Cx43 from HEI-OC1 cells to generate Cx43 KO
HEI-OC1 cells. Cx43 expression is exclusively located in structures composed of bone in
the mature inner ear (Cohen-Salmon et al., 2004; Kim et al., 2013). Surprisingly, neither
WT or Cx43 KO HEI-OC1 cells expressed Cx26 and Cx30, which are common
connexins found in the organ of Corti supporting cells. Cx43 ablation in HEI-OC1 cells
caused a large reduction in dye transfer; therefore, Cx43 is the predominant functioning
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connexin isoform expressed in HEI-OC1 cells. Other connexin isoforms expressed in the
inner ear in vivo: Cx31, Cx29, and Cx32, are unlikely to be expressed in HEI-OC1 cells
(Ahmad et al., 2003; Wingard and Zhao, 2015; Xu and Nicholson, 2013).
Ablating Cx43 and greatly reducing GJIC in HEI-OC1 cells provided us with a unique
model to study whether connexins and GJIC are involved in the development of
ototoxicity. Aminoglycoside antibiotics are readily taken up by hair cells through
mechanoelectrical transducer (MET) channels and induce hair cell death through ROS
formation (Alharazneh et al., 2011; Choung et al., 2009). HEI-OC1 cells have previous
been shown to be highly sensitive to aminoglycoside antibiotics even at doses as low as
5μM of gentamicin (Kalinec et al., 2003). In contrast, we have shown that neither WT or
Cx43 KO HEI-OC1 cells are sensitive to low or high doses of gentamicin or kanamycin
treatment. Both gentamicin and kanamycin were capable of inducing hair cell death in
cochlear cultures, which demonstrated that these antibiotics are indeed toxic to hair cells.
However, HEI-OC1 cells do not resemble mature hair cells but do express particular hair
cell molecular markers (Kalinec et al., 2003; Park et al., 2016). HEI-OC1 cells may be
less susceptible to aminoglycoside antibiotics compared to in vivo hair cells due to this
dissimilarity. Other researchers have reported that the culture conditions, such as passage
number, or different batches of HEI-OC1 cells may influence their sensitivity to
aminoglycosides (Cederroth, 2012). Additionally, some batches of HEI-OC1 cells may
have acquired resistance to aminoglycoside antibiotics since being isolated in 2003
(Cederroth, 2012; Kalinec et al., 2003). Chen et al., observed an absence of cell death in
HEI-OC1 cells treated with doses as high as 1mM gentamicin and 2mM kanamycin,
regardless of caspase 3 activation and even with direct evidence that gentamicin had
entered the cells. Thus, the absence of drug uptake does not explain why HEI-OC1 cells
are resistant to aminoglycosides. Other resistance mechanisms must exist, such as the
upregulation of drug efflux channels to limit toxicity (Chen et al., 2012). Overall, HEIOC1 cells were found to be inadequate for investigating mechanisms involved in
aminoglycoside induced hair cell death.
Aminoglycoside antibiotics and cisplatin both have been reported to induce ototoxicity
by triggering hair cell death, despite having distinct therapeutic mechanisms (Lanvers-
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Kaminsky et al., 2017). In comparison to aminoglycosides, both WT and Cx43 KO HEIOC1 cells were highly sensitive to cisplatin treatment. Cisplatin can enter hair cells
through organic cation transporters and copper transporter Ctr1, which are both expressed
in HEI-OC1 cells (More et al., 2010). The amplification of apoptosis due to GJIC has
widely been studied in the context of cancer cells treated with cisplatin but has not been
studied in relation to the development of ototoxicity (Arora et al., 2018; Ding and
Nguyen, 2012; Huang et al., 2001). Knock down of Cx43 using siRNA in HEI-OC1 cells
was found to moderately protect cells from cisplatin induced cell death when treated with
10μM of cisplatin for 48 hours (Kim et al., 2014). This protection was attributed to
increased activation of the MAPK survival signaling pathway when GJIC was inhibited
(Kim et al., 2014). Cell viability of Cx43 KO HEI-OC1 cells was greater than 100% and
significantly higher than WT HEI-OC1 cells when treated with 10μM of cisplatin for 24
hours. This protection against cell death of Cx43 KO HEI-OC1 cells did not persist at
higher concentrations of cisplatin or after 48 hours of treatment. Hormesis may be the
underlying mechanism responsible for the cell viability being greater than 100% at low
cisplatin dosage. Hormesis involves the induction of stimulatory effects in response to
low doses of toxins, such as anticancer drugs (Yoshimasu et al., 2015). Cx43 KO HEIOC1 cells may have enhanced their mitochondrial activity or proliferation to overcome
the toxic effects of low doses of cisplatin. WT and Cx43 KO HEI-OC1 cells were plated
at a higher cell density to enhance Cx43 gap junction plaque formation and GJIC in WT
cells to potentially provoke the bystander effect. Again, no differences in cisplatin
susceptibility between WT and Cx43 KO HEI-OC1 cells were detected. The bystander
effect has been proposed to amplify apoptosis by allowing the transfer of death signals
from damaged cells to surrounding healthy cells (Hong et al., 2012). However, the
bystander effect may not have been at play in WT HEI-OC1 cells because all cells within
a treatment group may have been equally targeted by cisplatin, which created no
dichotomy in cisplatin sensitivity between cells (Hong et al., 2012).
Although there were no differences in susceptibility to cisplatin induced cell death
between WT and Cx43 KO HEI-OC1 cells, the downstream apoptotic pathways were
altered. Apoptotic pathways were analyzed in WT and Cx43 KO HEI-OC1 cells treated
with 15μM and 30μM of cisplatin (within the therapeutic range of cisplatin) for 48 hours
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(Wang et al., 2010). Hair cells endogenously express antioxidant enzymes important for
eliminating ROS (Rybak et al., 2007). Hair cells are highly susceptible to ROS
accumulation because of their high metabolic activity and abundant mitochondria
(Jensen-Smith et al., 2012). Antioxidant enzyme expression and activity have been
documented to be inhibited by cisplatin due to direct interference (Cigremis et al., 2015;
Peres and da Cunha, 2013; Rybak et al., 2007). Other researchers have shown that the
induction of antioxidant enzyme expression increased cell viability of cisplatin treated
HEI-OC1 cells (Kim et al., 2018). The induction of antioxidant enzyme expression and
the exogenous administration of antioxidants are protective against cisplatin ototoxicity
and may be therapeutic targets (Jo et al., 2019; Kim et al., 2018; Kim et al., 2015).
Increased antioxidant enzyme mRNA expression in Cx43 KO HEI-OC1 cells after
cisplatin treatment suggests that they have enhanced protection from ROS accumulation.
Interestingly, this did not protect Cx43 KO HEI-OC1 cells from cell death since several
pathways are involved in the progression of apoptosis. Future research should focus on
whether antioxidant enzyme activity is additionally increased in cisplatin treated Cx43
KO HEI-OC1 cells.
ROS accumulation can activate the mitochondrial apoptotic pathway involving proapoptotic protein Bax and anti-apoptotic protein Bcl-2 (Matsumoto et al., 2016). The
ratio between Bax and Bcl-2 is an indicator of sensitivity towards apoptosis progression
when presented with a cellular stress (Siddiqui et al., 2015). Cisplatin has been
demonstrated to activate the mitochondrial apoptosis pathway within cells of the cochlea
and increase the Bax/Bcl-2 ratio (Garcia-Berrocal et al., 2007; Matsumoto et al., 2016).
WT HEI-OC1 cells may preferentially upregulate Bax more than Cx43 KO cells, which
is implied by the Bax/Bcl-2 ratio and increased Bax protein expression in WT cells. The
cytoplasmic tail of Cx43 is known to interact and facilitate Bax translocation to the
mitochondria to progress apoptosis (Sun et al., 2012). The cytoplasmic tail of Cx43 can
also upregulate Bax expression by interacting with the transcription factor p53 (Ferri and
Kroemer, 2001; Sun et al., 2012). WT HEI-OC1 cells may therefore undergo more
mitochondrial induced apoptosis compared to Cx43 KO HEI-OC1 cells after cisplatin
treatment because WT cells express Cx43.
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ER stress is an additional pathway that is activated after cisplatin treatment and can lead
to apoptosis independently from DNA damage (Mandic et al., 2003; Shi et al., 2016). ER
stress can be activated by cellular stressors that induce the accumulation of unfolded
proteins in the ER lumen (Gorman et al., 2012). The unfolded protein response (UPR) is
activated under moderate ER stress and enhances cell survival. Upregulation of the
chaperone protein BiP by UPR activation can reestablish ER homeostasis (Gorman et al.,
2012; Xu et al., 2014). BiP remains elevated under severe ER stress, which leads to the
activation of pro-apoptotic pathways (Xu et al., 2014). Cancer cells undergoing moderate
ER stress with increased BiP expression were resistant to cisplatin induced cell death (Shi
et al., 2016). BiP expression was increased in Cx43 KO HEI-OC1 cells after cisplatin
treatment; however, they were not resistant to cisplatin induced apoptosis. Therefore, ER
stress may have contributed more to the decreased cell viability of Cx43 KO HEI-OC1
cells after cisplatin treatment.
Proenzyme caspase 3 cleavage is a crucial component of the execution of apoptosis
(Garcia-Berrocal et al., 2007). Both WT and Cx43 KO HEI-OC1 cells had decreased cell
viability when treated with cisplatin, and they both had corresponding increased cleaved
caspase 3 expression. This indicates that both WT and Cx43 KO HEI-OC1 cells are
undergoing apoptosis in response to cisplatin rather than other cell death pathways such
as necrosis. The activation of cleaved caspase 3 is a similar outcome of both
mitochondrial apoptosis and severe ER stress (Rao et al., 2002). There is a complex
interplay between the two apoptotic pathways; therefore, neither WT nor Cx43 KO HEIOC1 cells exclusively activate one pathway (Ferri and Kroemer, 2001; Wei et al., 2001).
We speculate that the degree of GJIC may regulate the communication of different
signals and second messengers resulting in the activation of organelle specific apoptotic
pathways (Ferri and Kroemer, 2001). These results suggest that WT and Cx43 KO HEIOC1 cells may preferentially activate components of each apoptotic pathway depending
on their connexin expression and level of GJIC.
In summary, it is well known that connexins are indispensable for normal hearing and
cell survival within the cochlea (Chang et al., 2008; Zhao et al., 2006). Nevertheless, their
role in the development of ototoxicity has remained unstudied. Here, we have shown that
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connexin expression and GJIC in a cell line derived from the cochlea did not significantly
influence susceptibility towards cell death after ototoxic therapeutic treatment. Based on
these findings we suggest that connexins and GJIC may not be fundamental for the
development of ototoxicity. Our findings should be extended to the intricate inner ear in
vivo to further investigate whether connexins and GJIC may be a therapeutic target for
ototoxicity in future studies.
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Chapter 3
3 Cx26 mutations result in hearing loss through unique
mechanisms as demonstrated in cochlear-derived HEI-OC1
cells
3.1 Introduction
Nearly half of all inherited sensorineural hearing loss is attributed to mutations in the
connexin gene family (Chan and Chang, 2014). Connexins are gap junction proteins that
oligomerize into hexameric channels that can form hemichannels at the cell surface or
dock between adjacent cells (Goodenough and Paul, 2009). Gap junction formation
between cells facilitates the direct intercellular exchange of metabolites, ions, and small
molecules <1 kDa in a process known as gap junctional intercellular communication
(GJIC) (Alexander and Goldberg, 2003). The main connexin isoforms implicated in
hearing loss are connexin 26 (Cx26) and Cx30, which are abundantly expressed in two
independent gap junction networks in the cochlea: the epithelial and connective tissue
networks (Ahmad et al., 2003; Forge et al., 2003; Liu et al., 2009). The connective tissue
network exists between cells within the cochlear lateral wall (Jagger and Forge, 2015;
Kikuchi et al., 1995). The epithelial network is composed between supporting cells that
are precisely configured around the mechanosensory hair cells in the organ of Corti
(Jagger and Forge, 2015; Kikuchi et al., 1995). Cx26 and Cx30 have the capacity to cooligomerize and form heteromeric (mixed) channels within these networks (Martinez et
al., 2009). An influx of potassium ions (K+) into hair cells results in hair cell
depolarization and subsequent formation of electrical signals that are relayed to the brain
for hearing (Wangemann, 2006). These gap junction networks have been proposed to be
important in buffering and recycling K+ back into the endolymph fluid that bathes the
hair cells after hair cell stimulation (Kikuchi et al., 2000). Additionally, these networks
have been demonstrated to be vital in cochlear development, homeostasis, and nutrient
transfer (Chang et al., 2008; Liang et al., 2012; Zhao et al., 2006).
Connexins are composed of an amino-terminus and carboxy-terminus, four
transmembrane domains, two extracellular loops, and one intracellular loop (Sohl and
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Willecke, 2004). Approximately 135 different hearing loss mutations in the GJB2 gene
that encodes for Cx26 have been identified (Laird et al., 2017). These mutations occur
throughout all the protein domains of Cx26 (Martinez et al., 2009). Cx26 mutations can
be categorized based on having loss-of-function or gain-of-function properties (Laird,
2006). Loss-of-function mutations can result in defective trafficking of the Cx26 mutant
through the endoplasmic reticulum (ER) and Golgi apparatus, mutant misfolding or
oligomerization, and non-functional hemichannels and/or gap junctions (Kelly et al.,
2015; Laird, 2006). In contrast, aberrant oligomerization of a Cx26 mutant with other
connexin isoforms, formation of leaky hemichannels, formation of hyperactive
hemichannels and/or gap junctions are characteristics of gain-of-function mutations
(Press et al., 2017; Srinivas et al., 2018). Cx26 mutants with loss-of-function properties
typically only produce hearing loss as the pathological outcome and are characterized as
non-syndromic mutations (Kenneson et al., 2002). Cx26 mutants with gain-of-function
properties frequently result in syndromic hearing loss because these mutations induce a
skin disorder in addition to negatively affecting the cochlea (Srinivas et al., 2018). Gainof-function Cx26 mutants often induce skin disorders because of their inhibitory transdominant effects on other connexin isoforms expressed in the epidermis (Press et al.,
2017). Cx26 mutations can result in various severities of hearing loss and may induce
hearing loss through different mechanisms (Snoeckx et al., 2005). Because of the
diversity and quantity of hearing loss linked Cx26 mutations the exact mechanisms of
hearing loss remain unclear especially within a tissue-relevant setting.
Improper cochlear development is a pathological outcome of Cx26 mutant expression
and contributes to hearing loss (Chen et al., 2018; Jagger and Forge, 2015; Wang et al.,
2009). Cx26 knockout within the cochlea of mice induced the deformation of hair cells
and disrupted the formation of the tunnel of Corti, which is formed by supporting cells
(Anzai et al., 2015; Chen et al., 2018; Wang et al., 2009; Zhu et al., 2015). Hair cells and
supporting cells develop from a common progenitor within the pro-sensory domain of the
developing cochlea (Wu and Kelley, 2012). Specification of cell fate depends on the
proper coordination and timing of gene expression and is crucial for proper development
(Basch et al., 2016). The epithelial gap junction network expressing Cx26 begins to
develop around embryonic day 16 in mice (Frenz and Van De Water, 2000). Cx43 may
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also be expressed early on in cochlear development, however Cx43 expression is
negligible in the mature organ of Corti (Cohen-Salmon et al., 2004). Cx26 facilitates the
passage of miRNAs important in development and assists in the coordination of
differentiation (Zhu et al., 2015). Expression of Sox2 transcription factor is important for
the designation of the pro-sensory domain containing progenitor cells (Liu et al., 2018).
Terminal mitosis of progenitor cells occurs before the delineation of hair cells and
supporting cells (Chen and Segil, 1999). Increased expression of the transcription factor
Atoh1 is essential for the initiation of hair cell differentiation (Bermingham et al., 1999;
Chonko et al., 2013). Many proteins are exclusively expressed in mature hair cells, such
as the motor protein prestin, unconventional myosin proteins, and calcium binding
proteins (Hasson et al., 1995; Liu et al., 2014; Zheng et al., 2000). Nevertheless, the
mechanisms behind how Cx26 mutations and loss of GJIC influence gene expression and
the differentiation of hair cells within the organ of Corti remains unclear.
We selected four different missense GJB2 mutations resulting in either syndromic or nonsyndromic hearing loss in order to study their cellular localization and function in tissuerelevant HEI-OC1 cochlear cells. HEI-OC1 cells are an immortalized cell line isolated
from the region associated with the organ of Corti epithelium of mice cochlear explants.
HEI-OC1 cells are thought to be a common progenitor to hair cells and supporting cells.
These cells have previously been shown to downregulate supporting cell markers and
differentiate into hair cell-like cells under non-permissive culture conditions (Kalinec et
al., 2003; Park et al., 2016). We engineered HEI-OC1 cells to ablate the expression of
Cx43 (Cx43 KO) using CRISPR-Cas9, which rendered them with greatly reduced GJIC.
Hearing loss linked Cx26 mutants acquired three distinct cellular phenotypes when
expressed in HEI-OC1 cells. The dominant syndromic Cx26 mutant N54K had
trafficking defects and impeded Cx30 gap junction plaque formation. In contrast, the
dominant syndromic S183F mutant formed gap junction plaques incapable of transferring
dye and co-localized in the same gap junction plaques as wild-type (WT) Cx26, Cx30,
and Cx43. Both recessive non-syndromic Cx26 mutants (R32H and R184P) were retained
in intracellular vesicles including early endosomes and did not co-localize with Cx30.
Therefore, these four Cx26 mutants may contribute to unique pathways for hearing loss
in vivo. Additionally, the ablation of Cx43 and greatly reduced GJIC in Cx43 KO HEI-
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OC1 cells did not impede their partial differentiation into hair cell-like cells. Thus, Cx43
and GJIC may not be essential for hair cell differentiation in vitro.

3.2 Materials and Methods
3.2.1 Cell Culture and Reagents
House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were kindly provided by Dr.
Kalinec (House Ear Institute, Los Angeles, CA). HEI-OC1 cells were grown in high
glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Cat# 1190-044, Life
Technologies) supplemented with 10% fetal bovine serum and 2mM L-glutamine in
permissive conditions (33°C and 10% CO2). To induce hair cell-like cell differentiation,
HEI-OC1 cells that were 80% confluent were transferred into non-permissive conditions
(39°C and 5% CO2) for ten days and regular media was replenished every other day to
remove dead cells.

3.2.2 cDNA Constructs and Transfections
WT Cx26 and Cx26 mutations (N54K, S183F, R32H, R184P) were sub-cloned into
moxGFP vectors (Adgene) using the restriction enzymes XholI and BamHI. Sequences
were then verified by NorClone Biotech Laboratories. Cx26-RFP and Cx30-RFP were
generated as previously described (Berger et al., 2014). HEI-OC1 cells at 60%
confluency in six well dishes were transiently transfected with 1μg of the desired cDNA
construct using Mirus TransIT-LT1 Transfection Reagent (Cat# MIR2300, Mirus Bio
LLC) according to manufacturer’s instructions. Co-transfection of Cx26-RFP and Cx30RFP with Cx26 mutant constructs were done at a 1:1 ratio consisting of 0.75µg of each
cDNA vector to approximate equal protein expression. Cells were then fixed and
immunolabelled ~30 hours after a successful transfection.

3.2.3 Immunofluorescence
HEI-OC1 cells were grown on glass coverslips and were fixed with 4%
paraformaldehyde (PFA) for 10 minutes after being washed with phosphate-buffered
saline (PBS). HEI-OC1 cells were solubilized and blocked using 0.1% Triton X-100 +
3% bovine serum albumin (BSA) for one hour and then incubated with primary
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antibodies diluted in 0.1% Triton X-100 + 3% BSA overnight at 4°C. Primary antibodies
included: mouse anti-GM130 (1:500, Cat# 610822, BD Biosciences), rabbit anti-EEA1
(1:500, Cat# ab2900, abcam), rabbit anti-Cx43 (1:750, Cat# C6219, Sigma), rabbit antiprestin (1:200, Cat# AV447176, Sigma), and mouse anti-Sox2 (1:50, Cat# sc-365823,
Santa Cruz). Coverslips were then washed with PBS and incubated with secondary
antibodies diluted in 0.1% Triton X-100 + 3% BSA for one hour at room temperature.
Secondary antibodies included: goat anti-mouse 633 (Cat# A21052, Invitrogen), goat
anti-rabbit 568 (Cat# A11036, Invitrogen), and goat anti-mouse 555 (Cat# A21422,
Invitrogen). Coverslips were stained with Hoechst (1:1000 diluted in distilled H2O, Cat#
H3570, Molecular Probes) for ten minutes to visualize the nuclei and coverslips were
mounted using Airvol. Mice cochleae were dissected, cryosectioned, and immunolabelled
as previously described (Kelly et al., 2019). Images of transfected cells were captured
using airyscan and differentiation images were acquired using a consistent laser intensity
on a LSM800 Zeiss confocal microscope with a 63x oil immersion objective.

3.2.4 Fluorescence Recovery After Photobleaching (FRAP)
Cx43 KO HEI-OC1 cells were grown on 35mm glass bottom dishes coated with sterile
filtered type I rat tail collagen (Cat# 354236, Corning Life Sciences) diluted in 0.02M
acetic acid for one hour. Once cells were ~60% confluent they were transfected with 1μg
of either Cx26-GFP or S183F-GFP cDNA constructs using Mirus TransIT-LT1
Transfection Reagent. Approximately 30 hours after transfection, the cells were
incubated in Hank’s balanced salt solution (HBSS) containing 1µl/ml calcein-AM (Cat#
C3100-MP, Invitrogen) for five minutes at room temperature. Cells were then washed
with HBSS and replenished with warm media. The live cell imaging chamber was set at
33°C and 10% CO2 over a LSM800 Zeiss confocal microscope and images were captured
using a 63x oil immersion objective. Adjacent transfected cells with clearly identified gap
junction plaque formation were used to determine the function of Cx26 and the S183F
mutant. One transfected cell (region of interest (ROI)) was photobleached to <30% of
initial intensity and dye recovery was allowed to occur for five minutes. Throughout the
five minutes, an image was captured every 10 seconds and dye recovery within the ROI
was determined using the Time Series Analyzer V3 plugin on ImageJ. For each ROI,
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fluorescence recovery was measured using Recovery (%) = (Ft − F0/Fb) x 100 (Ft
fluorescence at each time point after photobleaching, F0: fluorescence at 0 s after
photobleaching, Fb: fluorescence before photobleaching) (Kim et al., 2014). Fluorescence
recovery was then plotted over five minutes as an average of three replicates each
consisting of a minimum of four pairs of transfected cells. The area under the curve was
then calculated and compared using an unpaired t-test. Negative controls consisted of dye
recovery within non-transfected Cx43 KO HEI-OC1 cells.

3.2.5 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was collected from permissive and non-permissive HEI-OC1 cells after
differentiation using RNeasy Mini Protocol for Isolation of Total RNA from Animal
Cells (Cat# 74106, Qiagen) and was converted to cDNA using the High Capacity cDNA
Reverse Transcription Kit (Cat# 4368814, Applied Biosystems). qRT-PCR was
conducted using PowerUp SYBR Green Master Mix (Cat# A25742, Life Technologies)
and the cycle conditions for each primer consisted of: 50°C for 2 min, 95°C for 2 min,
95°C for 5 s, 60°C for 15 s for 40 cycles, followed by a melt curve. The following
primers were used: 18s rRNA, the house keeping gene (forward, 5’GTAACCCGTTGAACCCCATT; reverse, 5’-CCATCCAATCGGTAGTAGCG), Atoh1
(forward, 5’- GAGTGGGCTGAGGTAAAAGAGT; reverse, 5’GGTCGGTGCTATCCAGGAG), calsequestrin (forward, 5’CGAGACTTGGGAGGATGACC; reverse, 5’- TCGGGGTTCTCAGTGTTGTC),
myosin VIIa (forward, 5’- TGGTACACTTGACACTGAAG; reverse, 5’CCATCGTTCAGCCTCTTGGT), nestin (forward, 5’GCTGGAACAGAGATTGGAAGG; reverse, 5’- CCAGGATCTGAGCGATCTGAC),
and Prox1 (forward, 5’- CGTTACGGGAGTTTTTCAATG; reverse, 5’CCTTGTAAATGGCCTTCTTCCA). mRNA levels were normalized to 18S rRNA levels
and measured using the ∆∆CT method. A two-way ANOVA and a Tukey’s post hoc test
was used to determine statistical significance between mRNA expression of permissive
and non-permissive WT and Cx43 KO HEI-OC1 cells. An un-paired t-test was used to
compare mRNA expression before and after differentiation within WT or Cx43 KO HEIOC1 cells.
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3.3 Results
3.3.1 The S183F mutant forms gap junction plaques while other hearing
loss linked Cx26 mutants are retained in intracellular compartments
To assess the localization of various hearing loss linked Cx26 mutants, WT Cx26 and
N54K, S183F, R32H, and R184P mutants were transiently expressed in Cx43 KO HEIOC1 cells. Cx43 KO HEI-OC1 cells were employed for these studies as the organ of
Corti is rich in Cx26 and Cx30, but generally devoid of Cx43. Thus, CRISPR-Cas9 was
used to ablate Cx43 from these organ of Corti derived cells. The localization of Cx26GFP was compared to the localization of two dominant syndromic Cx26 mutants (N54K
and S183F) and two recessive non-syndromic Cx26 mutants (R32H and R184P). Cx26
successfully trafficked to the plasma membrane in Cx43 KO HEI-OC1 cells (Fig. 3.1A).
In comparison to Cx26, the dominant syndromic Cx26 mutant N54K was fully retained
intracellularly and did not form gap junction plaques (Fig. 3.1A). In contrast, the S183F
mutant was able to traffic to the plasma membrane and form gap junction plaques (Fig.
3.1A). Additionally, both recessive non-syndromic Cx26 mutants did not form gap
junction plaques but appeared to be partially localized within intracellular vesicles (Fig.
3.1A). Some of these intracellular vesicles containing R32H and R184P immunolabelled
for EEA1, an early endosomal marker, and therefore may have reached the plasma
membrane before being endocytosed (Fig. 3.1B). Overall, S183F was the only hearing
loss linked Cx26 mutant tested that was capable of forming gap junction plaques in Cx43
KO HEI-OC1 cells.

3.3.2 The S183F mutant forms gap junction channels incapable of dye
transfer
To analyze whether the S183F mutant formed gap junction channels capable of dye
transfer like WT Cx26, calcein-AM dye transfer was measured using FRAP. Cell pairs or
clusters transiently expressing Cx26 or the S183F mutant were subjected to FRAP as a
surrogate for GJIC. Additionally, dye recovery within Cx43 KO cells not expressing
Cx26 or the S183F mutant were used as a negative control. S183F-GFP transfected cells
had significantly reduced calcein dye recovery after photobleaching compared to Cx26GFP expressing cells, assessed by the area under the curve (Fig.3.2).
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Figure 3.1. The S183F mutant was able to form gap junction plaques, while N54K,
R32H, and R184P mutants were retained within intracellular compartments. (A)
Representative micrographs of Cx26-GFP and various GFP-tagged hearing loss linked
Cx26 mutants transiently expressed in Cx43 KO HEI-OC1 cells. Cells were coimmunolabelled with GM130 (red) to visualize the Golgi apparatus and Hoechst (blue) to
visualize the nuclei. Cx26 and the dominant syndromic S183F mutant were able to form
gap junction plaques denoted by the white arrows. The dominant syndromic mutant
N54K and both recessive non-syndromic mutants (R32H & R184P) were retained within
intracellular compartments. (B) A portion of R32H and R184P mutants co-localized with
EEA1, an early endosomal marker, denoted by the white arrows. Scale bar = 10μm.
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Figure 3.2. S183F-GFP expressing Cx43 KO HEI-OC1 cells have negligible dye
transfer in comparison to Cx26-GFP. Cx43 KO HEI-OC1 cells engineered to express
Cx26-GFP or S183F-GFP and were loaded with gap junction permeable dye calcein-AM
(green). A selected cell with adjacent cells expressing Cx26 or the S183F mutant was
photobleached and dye recovery over 300 seconds was measured. Area under the curve
(AUC) of fluorescence recovery was measured. Cells expressing the S183F mutant had
significantly less dye recovery than WT Cx26 expressing cells, indicating that S183F
mutant expressing cells are impermeable to calcein-AM. The negative control consisted
of calcein-AM dye recovery within non-transfected Cx43 KO HEI-OC1 cells. Scale bar=
10μm. Data represents mean ± SEM of three independent experiments (** P< 0.01
unpaired t-test).
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3.3.3 N54K and S183F mutants do not display a dominant negative effect
on Cx26 localization
Since dominant Cx26 mutants are typically co-expressed with WT Cx26, we examined
whether GFP-tagged N54K and S183F mutants might alter the intracellular localization
of RFP-tagged Cx26. This may be informative of a possible mechanism underpinning
hearing loss in vivo. The intracellularly localized N54K mutant failed to form gap
junction plaques when co-expressed with Cx26 (Fig. 3.3). Additionally, the N54K mutant
did not fully prevent Cx26 from forming gap junction plaques but may have increased
Cx26 found in intracellular compartments, such as the Golgi (Fig. 3.3). In contrast, the
S183F mutant proceeded to traffic to the cell surface when co-expressed with Cx26-RFP
and both co-localized within the same gap junction plaques (Fig. 3.3). Overall, neither
dominant syndromic mutant blocked Cx26 from forming gap junction plaques, although
the N54K mutant appeared to impede the trafficking of Cx26.

3.3.4 The N54K mutant exerts a trans-dominant effect on Cx30 localization
Cx30 is also highly expressed in the organ of Corti and oligomerizes with Cx26 to form
gap junction plaques in vivo (Ahmad et al., 2003). When transiently expressed in Cx43
KO HEI-OC1 cells, Cx30 was able to form gap junction plaques and co-localized with
co-expressed Cx26 (Fig. 3.4A, B). Additionally, the hearing loss linked Cx26 mutants
were co-expressed with Cx30 to determine if the Cx26 mutants influenced Cx30
localization. The N54K mutant prevented Cx30 gap junction plaque formation, whereas
the S183F mutant co-localized with Cx30 within the gap junction plaques (Fig. 3.4B).
Both recessive non-syndromic mutants (R32H and R184P) remained localized to
intracellular compartments and did not hinder Cx30 trafficking (Fig. 3.4B). Overall, the
N54K mutant exhibited an inhibitory trans-dominant effect on the trafficking of Cx30.

3.3.5 The S183F mutant localizes within the same gap junction plaques as
endogenous Cx43
The expression of Cx43 in the mature organ of Corti is not fully elucidated, however
Cx43 is expressed throughout development of the human and mouse inner ear (CohenSalmon et al., 2004; Locher et al., 2015). Hearing loss linked Cx26 mutants would
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Figure 3.3. Cx26-GFP gap junction plaque formation is not disrupted when coexpressed with the N54K or S183F mutant. Representative micrographs of Cx43 KO
HEI-OC1 cells co-expressing Cx26-RFP and N54K-GFP or S183F-GFP. Cells were coimmunolabelled with GM130 (white) to visualize the Golgi apparatus and Hoechst (blue)
to stain the nuclei. Cx26 was able to form gap junction plaques when co-expressed with
either of the dominant syndromic mutants (N54K & S183F) denoted by the white arrows.
The N54K mutant appeared to co-exist with Cx26 within the Golgi apparatus, whereas
the S183F mutant co-localized with Cx26 within the same gap junction plaques. Scale
bar= 10μm.
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Figure 3.4. Cx30 gap junction plaque formation was impeded when co-expressed
with the N54K mutant. (A) Cx30-RFP was transiently expressed in Cx43 KO HEI-OC1
cells and co-immunolabelled with GM130 (white) and Hoechst to visualize the nuclei
(blue). Cx30 was capable of forming large gap junction plaques denoted by the white
arrows. (B) Cx30 when co-expressed with Cx26 or the S183F mutant localized within the
same gap junction plaques, denoted by the white arrows. The N54K mutant prevented
Cx30 gap junction plaque formation and both were retained within intracellular
compartments. Both recessive mutants, R32H and R184P, remained intracellularly and
did not co-localize with Cx30. Scale bar= 10μm.
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therefore be co-expressed with Cx43 throughout development of the in vivo inner ear. To
study whether Cx26 mutants exert a trans-dominant effect on the trafficking of Cx43, the
Cx26 mutants were expressed in WT HEI-OC1 cells expressing endogenous Cx43.
Previous studies have shown that Cx26 and Cx43 do not form heteromeric gap junctions
but are able to intermix in the same gap junction plaques (Falk, 2000; Gemel et al., 2004).
Both Cx26 and Cx43 formed gap junction plaques in WT HEI-OC1 cells, however, they
appeared to segregate within different regions of the plaques and therefore may not be
forming heteromeric channels (Fig. 3.5A, B). The N54K mutant did not co-localize in
gap junction plaques with Cx43 when expressed in WT HEI-OC1 cells (Fig. 3.5A). In
contrast, the S183F mutant co-localized with Cx43 and was evenly distributed throughout
the same gap junction plaques (Fig. 3.5A, B). This indicates that the S183F mutant may
have gain-of-function properties allowing it to potentially interact with Cx43. Both
recessive mutants (R32H and R184P) remained intracellularly and did not appear to
interfere with Cx43 gap junction plaque formation (Fig. 3.5A). We conclude that none of
the hearing loss linked Cx26 mutants exhibited a trans-dominant effect on the localization
of Cx43, however the S183F mutant may have acquired the ability to potentially interact
with Cx43 within gap junction plaques.

3.3.6 WT and Cx43 KO HEI-OC1 cells increase in size when cultured in
non-permissive conditions
To investigate whether disruptions in GJIC, potentially due to Cx26 mutations, is
involved in altered hair cell differentiation leading to hearing loss, Cx43 KO HEI-OC1
cells with greatly reduced GJIC were utilized. HEI-OC1 cells have previously been
shown to differentiate into hair cell-like cells under non-permissive conditions by
upregulating hair cell molecular markers (Kalinec et al., 2003). After ten days in nonpermissive conditions both WT and Cx43 KO HEI-OC1 cells had clusters of cells that
increased in cell size while other cells continued to proliferate or undergo apoptosis (Fig.
3.6A). To determine if a portion of WT HEI-OC1 cells had successfully differentiated,
we immunolabelled for the motor protein prestin, which is exclusively expressed in
mature outer hair cells. Prestin expression was observed in the mouse cochlea as a
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Figure 3.5. Endogenous Cx43 gap junction plaques persist in WT HEI-OC1 cells
expressing hearing loss linked Cx26 mutants. (A) Representative micrographs of WT
HEI-OC1 cells expressing Cx26-GFP and various hearing loss linked Cx26 mutants coimmunolabelled with GM130 (white) and stained with Hoechst (blue) to visualize the
nuclei. Cx26 and Cx43 both formed gap junction plaques, (B) however the connexin
isoforms appear to be localized within distinct regions of the same gap junction plaques.
The S183F mutant additionally formed gap junction plaques in WT HEI-OC1 cells and
(B) co-localized with Cx43 throughout the gap junction plaques. (A) N54K, and both
recessive non-syndromic mutants (R32H and R184P) remained intracellularly and did not
prevent Cx43 gap junction plaque formation. Scale bar= (A) 10μm, (B) 2μm.
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positive control around the outer hair cells, but prestin was not detected in either
permissive or non-permissive WT HEI-OC1 cells (Fig. 3.6B). This suggests that WT
HEI-OC1 cells did not successfully differentiate along the hair cell lineage. Additionally,
progenitor cell molecular markers would be expected to decrease after HEI-OC1 cells
transition from a progenitor state into hair cell-like cells. However, the transcription
factor Sox2 was equally expressed in both WT and Cx43 KO HEI-OC1 cells after
differentiation, further supporting the finding that these cells failed to fully differentiate
into hair cell-like cells (Fig. 3.6C). We concluded that WT and Cx43 KO HEI-OC1 cells
lack the capacity to differentiate fully into hair cell-like cells.

3.3.7 mRNA expression of mature hair cell markers increases in WT and
Cx43 KO HEI-OC1 cells under non-permissive conditions
To further assess whether WT and Cx43 KO HEI-OC1 cells have some capacity to
differentiate, total RNA was collected from cells cultured in permissive and nonpermissive conditions. The mRNA expression of Atoh1, a transcription factor expressed
during the initiation of hair cell development was not altered under non-permissive
conditions in either WT or Cx43 KO HEI-OC1 cells (Fig. 3.7A). Mature hair cell
markers calsequestrin and myosin VIIa mRNA expression both increased in Cx43 KO
HEI-OC1 cells in non-permissive conditions, whereas calsequestrin also increased in
non-permissive WT HEI-OC1 cells (Fig. 3.7A). Surprisingly, the mRNA expression of
progenitor/supporting cell marker Prox1 increased in non-permissive Cx43 KO HEI-OC1
cells compared to permissive Cx43 KO cells (Fig. 3.7B). The mRNA expression of the
intermediate filament protein nestin was not altered in non-permissive conditions (Fig.
3.7B). Overall, both WT and Cx43 KO HEI-OC1 cells may have initiated differentiation
by upregulating the mRNA expression of mature hair cell markers but failed to fully
differentiate into hair cell-like cells. The ablation of Cx43 did not affect the
differentiation potential of Cx43 KO HEI-OC1 cells.
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Figure 3.6. Both WT and Cx43 KO HEI-OC1 cells were larger but failed to increase
protein levels of key hair cell markers under non-permissive conditions. (A) Light
microscope images of WT and Cx43 KO HEI-OC1 cells in permissive conditions and
after ten days in non-permissive conditions. White arrows denote large cells that appear
to have undergone some level of hair cell-like cell differentiation. (B) Motor protein
prestin (red) was successfully detected in hair cells of a postnatal mouse cochlea cross
section but was not detected in WT HEI-OC1 cells grown in permissive or nonpermissive conditions. (C) Progenitor cell marker Sox2 (red) expression was detected in
HEI-OC1 cells cultured under all conditions. Green= phalloidin, Hoechst (blue)= nuclei.
Scale bar= (A) 100μm, (B) 10μm, (B) cochlea 20μm.
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Figure 3.7. Differential increases in the mRNA expression of hair cell molecular
markers in non-permissive HEI-OC1 cells. (A) There was no difference in the early
hair cell marker Atoh1 mRNA expression when cultured in non-permissive conditions in
either WT or Cx43 KO HEI-OC1 cells. WT and Cx43 KO cells had increased
calsequetrin mRNA expression when cultured in non-permissive conditions, and Cx43
KO HEI-OC1 cells additionally had increased myosin VIIa mRNA expression. (B) The
progenitor cell marker nestin mRNA expression was not altered, although Prox1 mRNA
expression increased in Cx43 KO HEI-OC1 cells cultured in non-permissive conditions.
Data represent mean ± SEM of four independent experiments comprised of two or three
independent Cx43 KO clones. (* P< 0.05, ** P< 0.01 two-way ANOVA and Tukey’s
post hoc, ★ P< 0.05 unpaired t-test).
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3.4 Discussion
Mutations in the GJB2 gene encoding for Cx26 comprise around 50% of all inherited
non-syndromic hearing loss cases (Chan and Chang, 2014; Kenneson et al., 2002). Over
135 different Cx26 mutations have been identified that result in varying severities of
hearing loss (Kenneson et al., 2002; Laird et al., 2017). The mechanisms by which each
of these Cx26 mutations results in hearing loss is not fully understood especially within
tissue-relevant cells. The different mechanisms that underpin hearing loss are extensive
due to the possibility of both loss-of-function and gain-of-function properties being
exhibited by Cx26 mutants (Kelly et al., 2015; Srinivas et al., 2018). In this study we
utilized tissue-relevant HEI-OC1 cochlear cells that share characteristics with hair cell
progenitor cells (Kalinec et al., 2003). We investigated the localization of two dominant
syndromic mutants: N54K and S183F, and two recessive non-syndromic mutants: R32H
and R184P. Three distinct cellular phenotypes were observed encapsulating the four
mutants studied. Two distinct phenotypes were detected between the dominant syndromic
mutants. The N54K mutant had impaired trafficking to the plasma membrane. The S183F
mutant was capable of forming gap junction plaques, however they were non-functional.
The N54K mutant exhibited a negative trans-dominant effect on Cx30 gap junction
plaque formation but did not interfere with Cx26 or Cx43 plaque formation. The S183F
mutant localized within the same gap junction plaques as Cx26 and Cx30. A gain-offunction property was exhibited by the S183F mutant by acquiring the ability to localize
in the same gap junction plaques as Cx43. Both recessive non-syndromic mutants
remained in intracellular compartments including early endosomes and did not localize
with Cx30 or Cx43. Thus, we have demonstrated that there are distinct mechanisms
underpinning hearing loss caused by syndromic and non-syndromic Cx26 mutants.
Connexins are composed of an intracellular amino-terminus and carboxy-terminus, four
transmembrane domains, two extracellular loops, and one intracellular loop (Sohl and
Willecke, 2004). Hearing loss linked Cx26 mutations have been identified in each protein
domain, which signifies the importance of each domain in the functionality of connexins
(Martinez et al., 2009; Xu and Nicholson, 2013). The localization and function of many
of these Cx26 mutants have been studied in non-tissue-relevant cells including Xenopus
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oocytes and HeLa cells (Bruzzone et al., 2003; Mani et al., 2009; Shuja et al., 2016; Xiao
et al., 2011). A large portion of Cx26 mutants displayed defective trafficking to the
plasma membrane which is categorized as a loss-of-function property (Martinez et al.,
2009; Xu and Nicholson, 2013). The majority of Cx26 mutations are recessively inherited
and produce non-syndromic hearing loss (Kenneson et al., 2002). A few Cx26 mutations
cause syndromic hearing loss, which are all inherited in a dominant manner (de ZwartStorm et al., 2008; Martinez et al., 2009). Many of the conserved residues between the
majority of connexin isoforms induce hearing loss when mutated in Cx26, including the
four mutants in this study: N54K, S183F, R32H, and R184P (de Zwart-Storm et al.,
2008; Maeda et al., 2009).
Both dominant syndromic mutants, N54K and S183F, are located in the extracellular
loops of Cx26. The two extracellular loops of connexins are important in the docking of
connexons between adjacent cells (Maeda et al., 2009; White and Bruzzone, 1996). The
substitution of asparagine to a lysine results in the N54K mutant and the skin pathology
Bart-Pumphrey syndrome (Richard et al., 2004). The palmar and knuckle skin of a patient
harbouring the N54K mutation with Bart-Pumphrey syndrome had a compensatory over
production of Cx30 (Richard et al., 2004). The overexpression of Cx30 may have
prevented the cytoplasmic accumulation of the N54K mutant within the skin.
Additionally, Cx30 and Cx43 localization was not disrupted in the patient’s skin (Richard
et al., 2004). In contrast, we observed no gap junction plaque formation by the N54K
mutant; moreover, Cx30 gap junction plaque formation was absent when co-expressed
with the N54K mutant, both of which may contribute to hearing loss in vivo. Localization
discrepancies may arise because connexin deficient cell lines, such as Cx43 KO HEIOC1 cells, are unable to induce the overexpression of Cx30. Asn54 is important for the
formation of hydrogen bonds with the adjacent connexon (Maeda et al., 2009). This interprotomer interaction may be disrupted and contribute to the lack of gap junction plaque
formation by the N54K mutant in HEI-OC1 cells. The lack of N54K mutant gap junction
plaque formation was also observed in HeLa and rat epidermal keratinocytes (Press et al.,
2017).
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The S183F mutant still forms gap junction plaques in HEI-OC1 cells even though the
mutation is located in an extracellular loop of Cx26. Ser183 may therefore not be
essential for connexon docking between adjacent cells. The S183F mutant arises from the
substitution of a serine for a phenylalanine within the second extracellular loop domain
and produces the skin disorder palmoplantar keratoderma (PPK) (de Zwart-Storm et al.,
2008). Gap junction plaques were also formed by the S183F mutant in connexin deficient
HeLa cells (Press et al., 2017). In accordance with other studies, the S183F mutant has
been found to form non-functional gap junctions indicated by the lack of dye transfer
(Press et al., 2017; Shuja et al., 2016). Additionally, Shuja et al., demonstrated that the
S183F mutant may be forming heteromeric connexons with Cx43 and trans-dominantly
inhibiting Cx43 gap junction function. Oligomerization with Cx43 is a characteristic of
PPK-associated Cx26 mutants (Shuja et al., 2016). The S183F mutant localized within
the same gap junction plaques as Cx43 in WT HEI-OC1 cells. Cx26 and Cx43 are
generally unable to oligomerize and remained segregated to different regions of gap
junction plaques (Falk, 2000). Thus, the S183F mutant expressed in HEI-OC1 cells may
have exhibited the gain-of-function property to aberrantly oligomerize with Cx43. The
N54K mutant did not co-localize with Cx43 in HEI-OC1 cells, which may contribute to
the development of different skin pathologies between the N54K and S183F mutants
(Shuja et al., 2016). The compatibility of connexin isoforms to oligomerize is thought to
involve a region between the amino-terminus and the second transmembrane domain, but
this is still speculative (Martinez et al., 2011). Interestingly, the S183F mutation is
located in the second extracellular loop and may unveil new residues important in the
formation of heteromeric channels. The S183F mutant also co-localized in the same gap
junction plaques as Cx26 and Cx30 in HEI-OC1 cells. Other studies have demonstrated
that Cx26 and Cx30 function is decreased by the S183F mutant, which may contribute to
S183F mutant induced hearing loss in vivo (Press et al., 2017; Shuja et al., 2016). Our
results further support the understanding that syndromic mutants induce hearing loss due
to their inhibitory trans-dominant effects on other connexin isoforms, in addition to lossof-function properties.
Intriguingly, Arg184 is the amino acid beside Ser183 within the second extracellular
loop; however, mutations of these residues produce vastly different phenotypes. The
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substitution of a conserved arginine to a proline at position 184 results in the recessive
non-syndromic R184P mutant (Mani et al., 2009). This arginine residue is important for
inter-protomer interactions between the second extracellular loop and the adjacent
connexon (Maeda et al., 2009). Multiple reports have shown that the R184P mutant has
impaired trafficking to the cell surface (Bruzzone et al., 2003; Mani et al., 2009). It has
also been reported that the R184P mutant may be able to traffic to the plasma membrane
but is incapable of forming gap junction plaques (Snoeckx et al., 2005; Xiao et al., 2011).
Additionally, the expression levels of the R184P mutant were decreased compared to WT
Cx26 in transfected HeLa cells. R184P mutant expression was decreased because of rapid
degradation due to the inability of the mutant to oligomerize into connexons (Mani et al.,
2009; Thonnissen et al., 2002). This correlates with our findings showing that the R184P
mutant partially localized in early endosomes, which are involved in the lysosomal
degradation pathway. The R184P mutant may have been recycled from the plasma
membrane into endosomes or entered the endosome-lysosome degradation pathway
directly from the ER. Other connexin mutants have been shown to be degraded through
the endosome-lysosome pathway (VanSlyke et al., 2000). The R32H mutant may also be
degraded through the endosome-lysosome pathway. The R32H mutation arises due to the
substitution of arginine for histidine in the first transmembrane domain (Mustapha et al.,
2001). This domain is important in the formation of the connexin channel pore (Maeda et
al., 2009). Additionally, Arg32 is important in intra-protomer interactions, which
facilitates proper folding and oligomerization into hexameric channels (Maeda et al.,
2009). The R32H mutant may be proceeding along the same degradation pathway as
R184P because of improper folding and oligomerization of the mutant. The R32H mutant
was incapable of reaching the plasma membrane and was retained in the ER in HeLa
cells (Xiao et al., 2011). We observed similar results in HEI-OC1 cells where the R32H
mutant was retained in intracellular compartments and was partially located in early
endosomes. Furthermore, both recessive non-syndromic mutants (R32H and R184P)
were retained in intracellular compartments and did not co-localize with Cx30 or Cx43 in
HEI-OC1 cells. This is the first study to analyze these two mutants within a tissuerelevant cell line and our findings support the notion that non-syndromic mutants do not
interfere with other connexin isoforms. Specifically, these results agree with previous
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research suggesting that non-syndromic mutants do not acquire gain-of-function
properties but result in hearing loss due to loss-of-function mechanisms (Martinez et al.,
2009).
Improper cochlear development is a pathological outcome of aberrant Cx26 expression
(Wang et al., 2009; Zhu et al., 2015). The potential for HEI-OC1 cells to differentiate into
hair cell-like cells was harnessed to study whether connexin expression and GJIC are
involved in hair cell development. Hair cells were deformed and the tunnel of Corti
formed by supporting cells was absent in conditional Cx26 null mouse models (Anzai et
al., 2015; Chen et al., 2012; Wang et al., 2009; Zhu et al., 2015). Transgenic mice
expressing the dominant Cx26 mutant R75W displayed delayed apoptosis during
cochlear development and the organ of Corti was malformed (Inoshita et al., 2014). WT
HEI-OC1 cells were not able to fully differentiate into hair cell-like cells expressing
protein markers of in vivo hair cells, including prestin. Surprisingly, prestin has
previously been reported to be expressed in HEI-OC1 cells (Kalinec et al., 2003; Park et
al., 2016). HEI-OC1 cells may have lost their potential to differentiate into hair cell-like
cells in non-permissive conditions since being isolated from cochlear explants in 2003
(Kalinec et al., 2003). Moreover, heterogeneity between different batches of HEI-OC1
cells has been observed (Cederroth, 2012). Our comparison of whether Cx43 KO HEIOC1 cells had an alternate capacity to differentiate was convoluted due to the inability of
WT HEI-OC1 cells to fully differentiate. We found that the lack of connexin expression
and reduced GJIC in Cx43 KO HEI-OC1 cells did not further influence HEI-OC1
differentiation. WT and Cx43 KO HEI-OC1 cells had increased mRNA expression of
mature hair cell markers in non-permissive conditions. Interestingly, Cx43 KO HEI-OC1
cells had increased Prox1 mRNA expression after being cultured in non-permissive
conditions. Only patches of WT and Cx43 KO HEI-OC1 cells increased in cell size and
partially differentiated in non-permissive conditions. A portion of the remaining
progenitor cells may have increased their expression of the progenitor/supporting cell
marker Prox1 in Cx43 KO HEI-OC1 cells. Conversely, progenitor cell marker Sox2
protein expression was expressed in both WT and Cx43 KO HEI-OC1 cells. This
indicates that both WT and Cx43 KO HEI-OC1 cells remained in a progenitor state and
did not fully differentiate in to hair cell-like cells. The mRNA expression of the
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transcription factor Atoh1, which is essential for the initiation of hair cell differentiation
in vivo, was not increased in WT or Cx43 KO HEI-OC1 cells in non-permissive
conditions (Bermingham et al., 1999). This further implies that HEI-OC1 cells do not
fully resemble hair cell-like cells in non-permissive conditions but only upregulate
particular mature hair cell molecular markers.
Hearing loss caused by mutations in the gene encoding for Cx26 has a large impact on
numerous populations worldwide (Tsukada et al., 2015). Our understanding on how these
mutations induce hearing loss is still emerging. This study conducted in cochlear-derived
cells enhances the understanding by which Cx26 mutants can generate hearing loss. The
syndromic mutants primarily exhibited distinct gain-of-function properties, such as
potential aberrant oligomerization and inhibitory trans-dominant effects on other
connexin isoforms. The non-syndromic mutants exhibited loss-of-function properties,
including defective trafficking to the plasma membrane and the absence of gap junction
plaque formation. Defective development of hair cells as a pathological outcome of
aberrant connexin expression was not evident in HEI-OC1 cells. An in vivo model
capable of expressing different hearing loss linked Cx26 mutants should be utilized in
future studies to investigate potential developmental abnormalities of the organ of Corti.
Personalized treatments for hearing loss should be developed in the future because
different Cx26 mutations generate hearing loss through a variety of distinct mechanisms.
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Chapter 4
4 General Discussion
Connexin expression and GJIC are important for cellular homeostasis, development,
survival, and many physiological processes throughout the body, including in the inner
ear (Alexander and Goldberg, 2003; Mese et al., 2007; Zhao et al., 2006). This thesis
analyzed various mechanisms by which connexins and GJIC contributed to the
development of hearing loss as the result of ototoxic damage and congenital Cx26
mutations. Hearing loss primarily occurs due to the death or dysfunction of the hair cells
in the organ of Corti (Lanvers-Kaminsky et al., 2017). Hair cells require the proper
environment and the underlying intricate organization of supporting cells to function and
survive (Wan et al., 2013). Acquired hearing loss can occur after treatment with ototoxic
therapeutics that induce hair cell apoptosis (Callejo et al., 2015; Choung et al., 2009).
Congenital Cx26 mutations are a very common cause of hearing loss, which disrupt
cochlear development and lead to hair cell death (Chen et al., 2018; Sun et al., 2009).
This discussion will integrate our results about acquired and congenital hearing loss with
the literature in relation to connexins. Limitations and potential therapeutic treatments
will additionally be discussed.
In chapter 2, we investigated the role of connexins and GJIC in susceptibility of HEIOC1 cells to cell death after treatment with ototoxic therapeutics. We found that the
ablation of Cx43 and reducing GJIC in HEI-OC1 cells did not reduce their susceptibility
to cisplatin induced cell death, as would be predicted by the bystander effect.
Surprisingly, HEI-OC1 cells were not sensitive to aminoglycoside antibiotics and may
have acquired resistance since being isolated from mouse cochlear explants in 2003
(Cederroth, 2012; Kalinec et al., 2003). In the literature only one study has utilized HEIOC1 cells to determine the role of GJIC in the development of cisplatin induced
ototoxicity (Kim et al., 2014). They found that the inhibition of GJIC in HEI-OC1 cells
reduced cell death after exposure to 10μM of cisplatin for 48 hours. Reduced cell death
was attributed to a decrease in the bystander effect and increased MAPK cell survival
signalling (Kim et al., 2014). We found that Cx43 KO HEI-OC1 cells with decreased
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GJIC were not protected from cisplatin induced cell death. Enhanced cell death due to
GJIC in response to cisplatin treatment in cancer cells has been extensively studied in the
literature (Arora et al., 2018; Ding and Nguyen, 2012; Huang et al., 2001). Of note, the
tissue environment has been shown to influence the effect GJIC has on neighbouring
cells when exposed to toxins (Hong et al., 2012; Perez Velazquez et al., 2003). HEI-OC1
cells were extracted from non-cancerous tissue and this characteristic may account for the
absence of the bystander effect in WT HEI-OC1 cells. WT and Cx43 KO HEI-OC1 cells
may have activated different apoptotic pathways leading to decreased cell viability after
cisplatin treatment. WT HEI-OC1 cells preferentially upregulated pro-apoptotic protein
Bax, which is involved in the mitochondrial apoptotic pathway. The carboxy terminus of
Cx43 is capable of interacting with Bax and accelerating Bax translocation to the
mitochondria to progress apoptosis (Sun et al., 2012). WT HEI-OC1 cells may
preferentially upregulate Bax protein expression because the carboxy terminus of Cx43
can additionally influence Bax expression levels through downstream signalling
pathways (Ferri and Kroemer, 2001; Sun et al., 2012). Cx43 KO HEI-OC1 cells show
increased mRNA expression of various antioxidant enzymes after cisplatin treatment;
therefore, they may have increased protection from ROS accumulation. However, Cx43
KO HEI-OC1 cells still had decreased cell viability after cisplatin treatment. Cx43 KO
HEI-OC1 cells show increased protein expression of the ER stress marker BiP after
cisplatin treatment. The upregulation of BiP has been shown to confer resistance to
cisplatin induced cell death by re-establishing ER homeostasis (Shi et al., 2016), however
Cx43 KO HEI-OC1 cells were still susceptible to apoptosis. Therefore, increased BiP
expression may indicate that cisplatin triggered severe ER stress and contributed to
apoptosis in Cx43 KO HEI-OC1 cells. Further downstream apoptosis markers, such as
CHOP and caspase-12 can be measured in future experiments to confirm that ER stress
exclusively induces apoptosis in Cx43 KO HEI-OC1 cells (Xu et al., 2014). The lack of
Cx43 and reduced GJIC may trigger Cx43 KO HEI-OC1 cells to undergo a different
apoptotic pathway than WT HEI-OC1 cells due to altered signalling pathways.
HEI-OC1 cells have previously been mentioned to resemble hair cell progenitor cells and
express hair cell molecular markers (Kalinec et al., 2003; Park et al., 2016). Hair cells
lack connexin expression; however, gap junction networks connect the supporting cells,

110

which are essential for hair cell survival (Kikuchi et al., 1995; Wan et al., 2013). In
summary, we found that ototoxic drug induced cell death is not dependent on connexin
expression or GJIC. This coincides with hair cells being highly susceptible to ototoxic
therapeutics, yet they lack connexin expression (Callejo et al., 2015; Lanvers-Kaminsky
et al., 2017). Nevertheless, HEI-OC1 cells are not an exact model for the intricate layout
of the cochlea and future studies should further determine the role of connexin expression
and GJIC on cell death within the in vivo inner ear. A limitation of utilizing HEI-OC1
cells to study connexins in the cochlea is they lack Cx26 and Cx30 expression, which are
the predominant isoforms expressed in the cochlea (Forge et al., 2003). Cx26 and Cx30
have different selectivity parameters for signalling molecules compared to one another
and in relation to Cx43 (Kanaporis et al., 2008; Weber et al., 2004). Cx26 gap junction
channels are permeable to anionic and cationic molecules; whereas, Cx30 channels only
allow the passage of cationic molecules (Martinez et al., 2009). Formation of heteromeric
Cx26 and Cx30 channels in the cochlea display distinct permeability properties compared
to homomeric channels (Martinez et al., 2009; Sun et al., 2005). Therefore, since Cx43 is
the only endogenously expressed connexin isoform in HEI-OC1 cells, the susceptibility
to cisplatin treatment may be altered when cochlear connexin isoforms are expressed.
Stable expression of Cx26 and Cx30 in Cx43 KO HEI-OC1 cells could further be utilized
to study cisplatin induced ototoxicity in relation to connexins. In conclusion, connexins
and GJIC may not be essential for the development of ototoxicity. Yet, the downstream
pathways involved in cisplatin induced ototoxicity may be altered by connexin
expression and the degree of GJIC.
HEI-OC1 cells were utilized in chapter 3 to analyze mechanisms of hearing loss as the
result of Cx26 mutant expression. Around 50% of all non-syndromic hearing loss cases
worldwide are due to mutations in the GJB2 gene encoding for Cx26 (Chan and Chang,
2014). We investigated the localization of four different hearing loss linked Cx26
mutants comprised of two dominant syndromic mutants: N54K and S183F, and two
recessive non-syndromic mutants: R32H and R184P. These mutants were expressed in
Cx43 KO HEI-OC1 cells and WT HEI-OC1 cells expressing endogenous Cx43. In
summary, three distinct localization patterns were observed between the four different
Cx26 mutants when expressed in HEI-OC1 cells (Table 4.1). Both dominant syndromic
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mutants, N54K and S183F, induce hearing loss and an associated skin disorder. Skin
disorders associated with syndromic Cx26 mutations arise due to the Cx26 mutant
exhibiting trans-dominant effects on other connexin isoforms expressed in the epidermis,
such as Cx30 and Cx43 (Press et al., 2017; Srinivas et al., 2018). This supports our
findings that the N54K mutant exhibited an inhibitory trans-dominant effect on Cx30
localization. The S183F mutant localized in the same gap junction plaques as Cx26,
Cx30, and Cx43. Other studies have shown that the S183F mutant had an inhibitory
trans-dominant effect on the function of these three connexin isoforms (Press et al., 2017;
Shuja et al., 2016). We found that the S183F mutant did not form channels capable of
transferring dye. The function of S183F mutant channels when co-expressed with other
connexin isoforms should be analysed in these tissue relevant cells in future studies. The
lack of N54K mutant gap junction plaque formation and the prevention of Cx30 gap
junction plaque formation likely contributes to hearing loss induced by this mutant. In
contrast, the S183F mutant likely induces hearing loss by inhibiting the function of Cx26
and Cx30 as described previously (Press et al., 2017; Shuja et al., 2016). The different
phenotypes displayed by the N54K mutant and the S183F mutant may be responsible for
their associated severities of hearing loss. Patients harbouring the N54K mutant have
severe hearing loss; whereas, patients with the S183F mutant develop moderate hearing
loss (Press et al., 2017). This suggests that the lack of gap junction plaque formation
rather than decreased gap junction plaque function leads to an increase in severity of
hearing loss. Both recessive non-syndromic mutants (R32H and R184P) are likely to
induce hearing loss due to their lack of gap junction formation. Cx30 gap junction plaque
formation was not altered by either non-syndromic mutants. Previous research has shown
that Cx30 is not fully able to compensate for the lack of Cx26 channels because Cx30 is
only permeable to cationic molecules (Cohen-Salmon et al., 2002; Qu et al., 2012).
Hearing loss still transpires even though Cx30 is capable of forming gap junction plaques
when co-expressed with either of these non-syndromic Cx26 mutants in the inner ear.
The movement of signaling molecules by GJIC is important for proper cochlear
development (Wang et al., 2009; Zhu et al., 2015). Cx26 ablation in mice leads to
embryonic death due to placental defects; therefore, many studies have utilized
conditional knockout mice specifically removing Cx26 from the cochlear gap junction
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Plaque Formation

Cx26

N54K

S183F

R32H

R184P

Cx26-RFP

Cx30-RFP

Localized in

Formed plaques

same plaques

No plaque

Cx26 formed

formation

plaques

Prevented Cx30
plaque
formation

Cx43
Localized to
distinct regions of
plaques

Cx43 formed
plaques

Localized in

Localized in

Localized in same

same plaques

same plaques

plaques

No plaque

Cx30 formed

Cx43 formed

formation

plaques

plaques

No plaque

Cx30 formed

Cx43 formed

formation

plaques

plaques

Formed plaques

Table 4.1. Summary of gap junction plaque formation of hearing loss linked Cx26
mutants expressed in HEI-OC1 cells. This table outlines the three distinct cellular
phenotypes observed between the four Cx26 mutants when expressed in HEI-OC1 cells.
The dominant syndromic mutants (N54K and S183F) displayed two different localization
patterns and hearing loss mechanisms. The recessive non-syndromic mutants (R32H and
R184P) displayed similar localization phenotypes.
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networks (Gabriel et al., 1998; Liang et al., 2012; Wang et al., 2009; Zhu et al., 2015).
Several studies attribute hearing loss associated with Cx26 knockout with cellular
degradation (Cohen-Salmon et al., 2002; Sun et al., 2009). However, other researchers
have suggested that aberrant cochlear development and deformation of hair cells is the
initial instigator of hearing loss and cellular degradation is a secondary outcome (Anzai et
al., 2015; Chen et al., 2018; Liang et al., 2012; Wang et al., 2009). The early ablation of
Cx26 is important for determining the role of Cx26 during cochlear development (Chen
et al., 2014; Wang et al., 2009). We utilized HEI-OC1 cells that have previously been
shown to differentiate into hair cell-like cells to study whether connexins and GJIC are
important in hair cell development (Kalinec et al., 2003; Park et al., 2016). Unfortunately,
WT HEI-OC1 cells did not fully differentiate into hair cell-like cells but only upregulated
the mRNA of mature hair cell markers. Cx43 KO HEI-OC1 cells did not have enhanced
or decreased differentiation compared to WT cells. Overall, the partial differentiation of
HEI-OC1 cells was not dependent on connexin expression or GJIC. HEI-OC1 cells are
not the optimal model to study cochlear differentiation in relation to connexins. The use
of conditional Cx26 knockout models have been valuable for deciphering when Cx26
expression is essential for proper development of the cochlea (Chen et al., 2014; Wang et
al., 2009). However, future in vivo studies should focus on expressing specific Cx26
mutants linked to hearing loss early during cochlear development. For example, the
S183F mutant is capable of localizing and potentially interacting with Cx43 which is
expressed in the epithelium of the developing cochlea (Cohen-Salmon et al., 2004; Shuja
et al., 2016). Cx43 function has been shown to be diminished by the S183F mutant;
therefore, different developmental abnormalities may be observed when Cx26 mutants
are expressed in comparison to conditional Cx26 knockout models (Shuja et al., 2016).
Our findings demonstrate that connexin expression and GJIC are not involved in the
development of ototoxicity but contribute to the activation of particular downstream
apoptotic pathways. Conversely, connexins and GJIC are very important for hearing,
which is demonstrated by the fact that Cx26 mutations induce hearing loss. We analyzed
various hearing loss linked Cx26 mutants to further decipher hearing loss mechanisms.
Overall, three distinct hearing loss mechanisms existed between the four different Cx26
mutants studied, and many more mechanisms likely exist due to the plethora of hearing
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loss linked Cx26 mutations. Understanding the underlying mechanisms of acquired and
congenital hearing loss is instrumental in the discovery of new therapeutic targets to
attenuate hearing loss.

4.1 Therapeutic strategies for hearing loss linked Cx26 mutations
and ototoxicity
Connexins are expressed in the majority of tissues in the human body (Laird and Lampe,
2018). Disruptions in connexin expression and GJIC due to mutations can manifest in a
wide variety of diseases (Laird and Lampe, 2018; Srinivas et al., 2018). The use and
discovery of therapeutics targeting connexins are becoming more prevalent to circumvent
these disease states. Many therapies are centered around Cx43 because this isoform is
ubiquitously expressed in the human body and is the most widely studied (Laird and
Lampe, 2018). For example, a drug developed by the company CoDa Therapeutics has
been shown to reduce Cx43 expression levels in order to enhance wound healing (Laird
and Lampe, 2018; Qiu et al., 2003). The topical administration of wound healing
therapeutics is a major advantage to achieve high drug concentrations at the targeted area
(Qiu et al., 2003). In comparison, access to connexin channels in the inner ear to treat
hearing loss is limited. At this time the only treatment for deaf patients are cochlear
implants or hearing aids in patients with moderate hearing loss (Zhang et al., 2018). This
is despite the large impact Cx26 mutations have on people worldwide. Potential future
therapeutic strategies for Cx26 linked hearing loss primarily involve gene therapy
techniques (Fukunaga et al., 2016; Iizuka et al., 2015; Lee and Park, 2018; Zhang et al.,
2018). Gene therapy may have utility within the cochlea because it is a closed system and
a variety of viral vectors are available for gene delivery (Cooper et al., 2006; Sacheli et
al., 2013). These viral vectors can enter the inner ear through the tympanic membrane,
the round window or a cochleostomy to allow for drug delivery into the scala media
(Sacheli et al., 2013; Zhang et al., 2018). Gap junction formation and function have been
restored in conditional Cx26 knockout mouse models through the administration of WT
Cx26 by viral gene therapy (Iizuka et al., 2015; Yu et al., 2014). Early intervention is
important to prevent developmental abnormalities and cellular degradation associated
with the lack of Cx26 (Iizuka et al., 2015). Personalized gene therapy may be required
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depending on the distinct loss- or gain-of-function mechanisms that different Cx26
mutants exhibit (Laird and Lampe, 2018). A major limitation for gene therapy treatment
in humans with Cx26 mutations is that cochlear development is completed in utero;
whereas, the mouse inner ear continues to develop postnatally (Chen et al., 2018).
Interestingly, gene therapy has been used in mice in utero (Bedrosian et al., 2006). Gene
therapy has also been utilized in the prevention of cisplatin induced ototoxicity. For
example, introduction of the gene encoding for X-linked inhibitor of apoptosis (XIAP),
an inhibitor of caspases, prevented hair cell loss within the cochlea after cisplatin
treatment (Cooper et al., 2006). Understanding the downstream pathways involved in
hearing loss due to mutations or ototoxicity may allow for the discovery of other potential
treatment targets. For example, exogenous antioxidants have been found to reduce the
development of ototoxicity because the formation of ROS is a major component of hair
cell apoptosis (Callejo et al., 2015; Jo et al., 2019). The trans-differentiation of supporting
cells into hair cells is a potential technique to regenerate hair cells after damage from
ototoxicity (Lee and Park, 2018). Trans-differentiation has been effective by inducing
Atoh1 gene expression in supporting cells of the mature guinea pig cochlea which
proceeded to differentiate into new hair cells (Kawamoto et al., 2003). Stem cell therapies
may also be a future therapeutic strategy to regenerate damaged hair cells; however,
many limitations still exist such as implantation and the potential for tumorigenesis (Han
et al., 2010; Zhang et al., 2018). Overall, there are many potential treatments for the
reversal of hearing loss in patients with congenital Cx26 mutations or ototoxicity. As
more information is discovered about the role of connexins and GJIC in the development
of ototoxicity in vivo, connexins additionally may be a therapeutic target to alter
downstream apoptotic pathways.
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